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Abstract 
Allogeneic bone marrow transplantation (allo-BMT) is a potentially curative therapy for patients 
with cancer and hematological disorders.  However, its success is limited by graft-versus-host 
disease (GVHD).  During acute GVHD, donor T cells attack host epithelial tissues to trigger 
intestinal, skin, and thymic damage.  Less than 50% of patients who manifest with acute GVHD 
symptoms respond to corticosteroid therapy, underscoring the need to develop better therapeutic 
strategies.  Notch signaling has emerged as a critical regulator of T cell alloimmunity after allo-
BMT.  During allo-BMT, Notch signals are mediated by Notch1/2 receptors and Delta-like1/4 
ligands.  Systemic inhibition of Delta-like1/4 Notch ligands with neutralizing antibodies results 
in long-term protection from acute GVHD.  In this thesis, I first investigated the spatial and 
temporal regulation of Notch signals during allo-BMT.  I found that a single dose of Dll1/4-
neutralizing antibodies at the time of allo-BMT was sufficient to confer long-term protection 
from GVHD mortality.  In contrast, delayed administration of antibodies by only two days failed 
to protect from GVHD.  Together, these data identified a critical early period of Notch activity 
that promotes GVHD pathogenesis.  To determine the cellular source(s) that delivered Notch 
signals to alloreactive T cells during this window of activity, I genetically inactivated Dll1 and 
Dll4 Notch ligands within donor hematopoietic, host hematopoietic, and host nonhematopoietic 
tissues. Mice lacking Dll1 and Dll4 expression within their donor and host hematopoietic tissues 
remained sensitive to GVHD.  In contrast, mice that lacked Dll1 and Dll4 expression selectively 
within Ccl19+ fibroblastic cells were profoundly protected from GVHD lethality.  Thus, these 
data revealed that Ccl19+ fibroblasts deliver early Notch signals to alloantigen-
  ix 
specific T cells.  Next, I developed a novel model of acute GVHD with alloantigen-specific 4C 
CD4+ donor T cells to study molecular events during the critical 48-hour period of Notch 
activity.  Notch inhibition in alloantigen-specific T cells preserved early activation marker 
expression, IL-2 production, and initial proliferation.  In contrast, Notch inhibition impaired 
IFNγ and IL-17 proinflammatory cytokine production and reduced both mTORC1 and 
Ras/MAPK activity.  Transcriptional profiling during T cell priming revealed that Notch 
inhibition diminished transcription of an assortment of cytokines, cytokine receptors, and a 
subset of Myc target genes.  Collectively, my data demonstrated that fibroblastic niches deliver 
critical Notch signals to alloantigen-specific T cells during the first two days after allo-BMT.  
These early Notch signals were essential for acquisition of effector functions but not for initial 
proliferation.  Work in this thesis introduces the novel concept that early interactions between 
donor alloreactive T cells and host fibroblastic niches dictate the long-term outcome of GVHD.  
A deeper understanding of these interactions could lead to exciting new therapies for alloimmune 
and autoimmune disorders. 
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Chapter 1 
Introduction to Notch signaling and T cell alloimmunity1 
 
Alloreactive T cell immunity 
Allogeneic T cell responses drive immune reactivity against foreign tissue antigens. 
Alloimmunity plays an essential role in several situations of high medical significance. Host 
alloreactive T cells mediate immune rejection of implanted organs after solid organ 
transplantation (e.g. heart, lung, liver or kidney transplantation). With up to 100,000 organ 
transplants performed each year worldwide, T cell-mediated immune rejection represents a 
sizable public health problem. Current medical practice involves administration of life-long 
global immunosuppression (e.g. calcineurin inhibitors) to prevent organ rejection and 
corticosteroids to treat breakthrough rejection. This strategy is more successful for acute than for 
chronic rejection. In addition, life-long immunosuppression is associated with high costs and side 
effects, including increased risk of opportunistic infections and secondary malignancies. As an 
alternative, researchers have investigated strategies to induce host tolerance to the implanted 
organ, for example by interference with costimulatory molecules [1] or with non-myeloablative  
                                                            
1 Excerpts taken from: 
 
Chung J, Maillard I. Notch signaling in alloreactive T cell immunity. Current Topics in 
Microbiology and Immunology, 360: 135-150, 2012. PMID 22689203 
 
Chung J, Riella LV, Maillard I. Notch signaling in transplant rejection. Am J Transplant. 2016 Apr 1. 
PMID 27037759 
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hematopoietic cell transplantation [2, 3]. At this stage, these strategies have not translated into 
treatments that can be used in routine clinical practice. 
After allogeneic bone marrow or hematopoietic cell transplantation (allo-BMT), rejection is 
rare due to the immunosuppressive effects of the conditioning regimen on the recipient [4]. 
However, mature donor-derived T cells present in the transplant inoculum drive reactivity to 
alloantigens in host tissues and host-derived tumors [4-6]. Efficient donor T cell-mediated graft-
versus-tumor (GVT) activity results in cancer cell killing [4, 7-9]. This is essential for the 
success of allo-BMT since the procedure is performed most often for patients with leukemia, 
lymphoma or other hematological malignancies (>75% of the ~25,000 allo-BMTs performed 
worldwide each year). Unfortunately, GVT is often associated with reactivity of donor T cells 
against normal host tissues, leading to graft-versus-host disease (GVHD). GVHD is the most 
significant complication that limits the success and broad applicability of allo-BMT. Despite the 
universal use of potent immunosuppression in allo-BMT recipients, acute and chronic GVHD 
still occur in a substantial fraction of patients. Although intensifying the degree of global 
immunosuppression decreases the risk of GVHD, it comes at the price of impairing GVT 
efficiency. As a result, patients experience less GVHD but more tumor relapses, and thus no 
improvement in their overall survival [4, 10]. Therefore, progress in the field will require 
identification of new approaches to decrease GVHD severity without eliminating efficient GVT. 
Alloantigens can be associated with the major histocompatibility complex (MHC), or 
independent of it (“minor histocompatibility antigens”) [6]. Priming and differentiation 
ofalloreactive T cells occurs in several steps (Fig. 1.1) [5, 6]. Tissue damage and inflammation 
trigger activation and maturation of APCs through Toll-like receptor signaling and other innate 
pathways [11]. In allo-BMT, toxic conditioning regimens including total body irradiation and/or 
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Figure 1.1. Regulation of alloreactive T cell activation and differentiation 
Signals from the innate immune system activate antigen-presenting cells (APCs) and enable them to 
present alloantigens to naïve T cells in the presence of costimulatory signals and/or Notch signaling. 
Recent literature suggests that nonhematopoietic cells (noted by the question mark) can also serve as 
APCs.  Notch ligands are provided by APCs or other cell types. Upon activation, naïve T cells become 
effector T cells, and mediate graft rejection, graft-versus-host disease, and/or graft-versus tumor effects. 
 
chemotherapy contribute to APC activation and maturation. Activated APCs expressing 
costimulatory molecules prime naïve alloreactive T cells. In mouse allo-BMT models, host DCs 
play a dominant role in stimulating donor-derived alloreactive CD8+ T cells rapidly after 
transplantation [12-14].  Donor APCs are important in certain settings as well [15].  
Interestingly, recent work suggests that nonhematopoietic APCs also play a critical role in 
driving CD4+ T cell alloreactivity [81, 82].  Alloreactive T cells undergo activation, proliferation 
and expansion in lymphoid tissues. These cells then acquire effector functions through 
differentiation along various CD4+ and CD8+ T cell lineages. Much work has been performed to 
understand how effector pathways are regulated in alloreactive T cells, and this will be discussed 
later as it relates to Notch signaling in these cells. After priming in lymphoid organs, effector T 
cells undergo chemokine-directed migration into target tissues, mediating rejection (solid organ 
transplantation), as well as GVHD and GVT (allo-BMT) [16]. Clinically important targets of 
GVHD include the skin, intestine, liver, lung and thymus. Other immune cells collaborate with T 
  4 
cells in inducing tissue damage, especially in the chronic phase of the response. Activation of 
conventional T cells occurs simultaneously with activation and expansion of regulatory T cells, 
which play a critical role in the outcome of the alloreactive T cell response [4, 17-19]. 
Overview of Notch signaling 
Notch signaling is a highly conserved cell-to-cell communication pathway triggered by 
Notch ligand-receptor interactions between adjacent cells (Fig. 1.2) [20, 21]. In mammals, four 
Notch receptors (Notch1-4) have been identified in addition to five Notch ligands of the Jagged 
(Jagged1/2) and Delta-like families (Dll1/3/4). Jagged1/2 and Dll1/4 have agonistic properties, 
while Dll3 functions as a natural antagonist of the pathway [20]. Notch ligand-receptor 
interactions induce sequential proteolytic cleavage of the receptor by an ADAM family 
metalloprotease (ADAM10) and by the γ-secretase complex, ultimately releasing intracellular 
Notch (ICN) into the cytoplasm [20, 21]. ICN migrates into the nucleus where it interacts with a 
DNA-binding transcription factor referred to as CSL (CBF1/Suppressor-of-hairless/Lag-1) or 
RBP-Jκ (encoded by Rbpj). Upon Notch activation, CSL and ICN nucleate a large transcription 
activation complex that recruits a member of the Mastermind-like (MAML) family and other co-
activators to mediate transcriptional activation of Notch target genes [20-22].  
In the hematopoietic system, Notch was first identified for its oncogenic activity in T cell 
acute lymphoblastic leukemia [23, 24]. Recent studies in Notch-driven cancer cell lines detected 
binding of CSL and ICN at thousands of genomic sites [25]. However, only a fraction (<10%) of 
these sites appeared dynamically regulated by Notch signaling. Regulated sites were enriched for 
concomitant binding of specific transcription factors, suggesting context-specific regulation of 
the Notch target gene landscape by cooperating factors. Moreover, the majority of dynamic 
Notch-binding sites were located in distant elements with superenhancer features, suggesting that 
  5 
Notch is involved in long-range chromatin regulation [26]. Additional studies about the 
molecular mechanisms of Notch-mediated transcriptional activation will be essential to 
understand the context-specific effects of the Notch pathway. 
At physiological levels of signaling, Notch is required at early stages of T lineage 
development in the thymus [22, 27-30]. The effects of Notch are regulated in vivo through tight 
control of signaling intensity [31-33]. Lymphoid progenitors experience a sharp increase in 
Notch signaling upon entry into the thymus [29, 30] as a result of their exposure to a high density 
of the Notch ligand Delta-like-4 in the thymic epithelium [34]. High levels of Notch signaling 
are maintained until progenitors successfully cross the pre-T cell receptor checkpoint, after 
which signaling intensity is rapidly downregulated [30, 35-39]. Downstream of this checkpoint, 
CD4+CD8+ double positive thymocytes experience little if any Notch signaling when undergoing 
positive and negative selection. Thus, unlike forced induction of Notch signaling, Notch 
blockade in DP thymocytes does not interfere with T cell development [40-44]. 
In addition to the effects of Notch signaling in T cell development, increasing attention is 
being devoted to its role in peripheral T cell immunity [32, 33, 45-47]. Mature T cells 
predominantly express Notch1 and Notch2 receptors, which can engage Notch ligands during 
immune responses [48-50].  Toll-like receptor-mediated signals induce expression of Delta-like 
ligands in dendritic cells (DCs) and other antigen-presenting cells (APCs) [51-54]. Additional 
sources of Notch ligands may be available to T cells in tissues (e.g. from stromal cells, vascular 
structures or epithelial elements). Altogether, this sets the stage for a highly regulated context-  
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Figure 1.2. Overview of Notch signaling 
Mammalian Notch signaling is initiated by interactions between Notch receptors (Notch1-4) and Notch 
ligands (Delta-like 1,3,4; Jagged 1,2). Ligand-receptor binding triggers two sequential proteolytic 
cleavages of the Notch receptor, releasing the intracellular domain of Notch (ICN) into the cytoplasm. 
Upon entry into the nucleus, ICN forms a transcriptional activation complex with the transcription factor 
[55] CSL (CBF1/Suppressor-of-hairless/Lag-1), a member of the Mastermind-like (MAML) family, and 
other coactivators such as p300. ICN/CSL transcriptional complexes often assemble adjacent to other 
TFs, and can regulate Notch target gene expression proximally through promoter binding or distally 
through enhancer binding and long-range interactions. 
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dependent exposure of T cells to Notch signaling in different immune responses, with specific 
roles for individual Notch ligands and receptors. 
Complementary gain-of-function and loss-of-function experiments have been used 
extensively to study Notch in lower organisms and mammals. Although this approach has often 
proven to be fruitful, caution is required when Notch signaling intensity is tightly regulated. For 
example, Notch stimulation and Notch blockade may not have opposite effects in cells 
experiencing a low intensity of Notch signaling, as shown in DP thymocytes or in adult 
hematopoietic stem cells [40, 41, 44, 56-60]. In addition, forced exposure to Notch ligands or 
forced signaling through individual Notch receptors may have functional consequences that do 
not represent the in vivo function of the pathway. These considerations apply to the study of 
Notch in mature T cells. Although in vitro studies and gain-of-function experiments can generate 
useful working hypotheses, we believe that optimal experimental systems should involve 
stringent Notch loss-of-function systems applied in vivo.  
Early work on Notch signaling in T cell alloreactivity and tolerance 
Initial studies exploring a potential role for Notch signaling in mature T cell function and 
alloreactivity relied heavily on gain-of-function strategies. Lamb and coworkers were the first to 
spark interest in a role for Notch as an inducer of tolerance [61]. While studying T cell responses 
against a house dust mite protein, they engineered mouse dendritic cells (DCs) to overexpress the 
Notch ligand Jagged1. Adoptive transfer of antigen-pulsed Jagged1-overexpressing DCs led to 
antigen-specific hyporesponsiveness. Building on this concept, the Brenner group tested the 
ability of Jagged1-overexpressing antigen-presenting cells to modulate responses to alloantigens 
or viral antigens [62, 63]. Using Jagged1-transduced Epstein Barr Virus-transformed 
  8 
lymphoblastoid cell lines, they observed decreased T cell reactivity and evidence for 
transferrable suppressive effects. Similar outcomes were described in an in vivo cardiac allograft 
model, when Dallman and colleagues adoptively transferred mouse L cell fibroblasts engineered 
to overexpress MHC alloantigens and the Notch ligand Dll1 [64]. Although Dll1-overexpressing 
L cells delayed allograft rejection in a CD8+ T cell-dependent manner, it is unclear whether the 
effects were the result of direct engagement of Dll1 with Notch receptor in T cells. Similar 
observations were reported recently upon in vivo transfer of a Jagged1-transduced dendritic cell 
line in combination with CD40 blockade [65]. Altogether, these studies suggested that inducing 
artificially high Notch signals in T cells could generate a state of antigen-specific tolerance. 
In parallel, other laboratories observed that expression of specific Notch ligands could be 
induced by innate stimuli in professional antigen-presenting cells (APCs) [51, 53]. In coculture 
systems, Delta-like or Jagged Notch ligands within APCs was reported to promote skewing of T 
cell differentiation towards the T helper 1(Th1) vs. Th2 lineage, respectively [51, 66], although 
dichotomous inductive effects of Delta-like and Jagged Notch ligands were not detected in 
subsequent studies [67]. Collectively, while helpful for recognizing an important role for Notch 
in T cell alloreactivity, the use of artificial ex vivo conditions and overexpression models led to 
conclusions that were contradictory and have to be interpreted with caution.  Subsequent in vivo 
loss-of-function studies on mature T cells identified an even broader range of effects of Notch on 
both CD4+ and CD8+ T cell reactivity and function [68-70], many of which are discussed later in 
the “Mechanistic Considerations” section of this chapter. 
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In vivo studies of Notch signaling in allograft rejection 
In recent years, several groups have used genetic and pharmacological loss-of-function 
approaches to evaluate the in vivo effects of Notch signaling in alloreactive T cell responses, 
both in the setting of allograft rejection (Table 1.1A) and in graft-versus-host disease (GVHD) 
(Table 1.1B) [71-78]. An emerging consensus across these studies indicates that Notch signaling 
is a major pro-inflammatory pathway in T cell alloimmunity, and that Notch inhibition can 
dampen both allograft rejection and GVHD.  Thus, the true in vivo functions of Notch signaling 
appear to be diametrically different from the tolerogenic effects first detected using artificial 
gain-of- function strategies [61-64]. Furthermore, these studies identify Notch inhibition as a 
new promising therapeutic approach to mitigate the damaging consequences of T cell 
alloreactivity. 
Riella and coworkers used monoclonal antibodies to target the Notch ligand Dll1 in a MHC-
mismatched cardiac allograft transplantation model [75]. Systemic anti-Dll1 antibodies delayed 
allograft rejection when provided in conjunction with costimulatory blockade in Cd28-deficient 
mice or in recipients treated with CTLA4-Ig. Protection was associated with decreased 
production of IL-2, interferon gamma (IFNg), IL-6 and IL-17 by donor-specific T cells, but with 
increased production of the Th2 cytokines IL-4 and IL-5. In this model, the protective effects of 
anti-Dll1 antibodies were lost when transplantation was performed in STAT6-deficient recipients 
or upon concomitant IL-4 neutralization, indicating that increased IL-4 production was important 
to delay rejection. This paper was the first to demonstrate a pathogenic effect of Notch signaling 
and a therapeutic benefit of Notch inhibition in allograft rejection in vivo, in stark contrast to 
earlier literature using artificial gain-of-function systems. Because this study was performed in 
the presence of costimulatory blockade and only examined the effect of Dll1 inhibition but not 
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other Notch ligands, it was unclear if similar outcomes would be observed without costimulatory 
blockade or upon more complete Notch inhibition. Due to the systemic nature of Dll1 inhibition, 
it could not be determined if the protective effects of anti-Dll1 antibodies were related to their 
direct effects on T cells and/or on other cell types. 
To achieve a higher level of Notch inhibition in alloreactive T cells, Wood et al. studied a 
MHC-mismatched heart allograft model in mice expressing the pan-Notch inhibitor dominant 
negative Mastermind-like1 (DNMAML) specifically in T cells [74]. DNMAML blocks 
transcriptional activation downstream of all Notch ligands and receptors [22]. In Cd4-Cre x 
ROSA26DNMAML mice, DNMAML expression first arises in CD4+CD8+ double positive [79] 
thymocytes without interfering with early Notch-dependent stages of T cell development [42].  
Thus, mature CD4+ and CD8+ T cells develop normally from DP thymocytes in these mice, but 
cannot respond to Notch signals during subsequent T cell responses due to DNMAML 
expression. This strategy is highly effective in capturing the overall effects of Notch signaling in 
T cell immunity, irrespectively of the individual Notch ligands and receptors involved [71, 73]. 
DNMAML mice rejected MHC-mismatched hearts in a delayed fashion [74]. Although the delay 
was relatively modest in the absence of other interventions, it was observed in the absence of 
costimulatory blockade, suggesting that complete Notch inhibition in T cells could achieve 
higher protection from rejection than the level of protection seen upon partial Notch inhibition 
with anti-Dll1 antibodies [74, 75]. Importantly, upon concomitant CD8 depletion prior to 
transplantation, DNMAML expression led to markedly enhanced protection, with a median 
allograft survival of >40 days. These findings suggested that CD4+ alloreactive T cells were 
particularly sensitive to Notch inhibition. Mechanistically, DNMAML led to decreased 
production of both IFNg and IL-4 by donor-reactive T cells, decreased immune cell infiltration 
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and an increased regulatory T cell (Treg)/effector T cell [80] ratio within the graft. DNMAML 
recipients also showed delayed appearance of graft-specific alloantibodies, suggesting a role for 
Notch in T cell help to allospecific B cell responses. 
Building on their observations from studies using genetic pan-Notch inhibition in T cells, 
Wood et al. assessed the impact of humanized anti-Dll1 and anti-Dll4 antibodies, alone or in 
combination, on allograft rejection [74]. This approach was chosen given the effects of Dll1 in 
transplant rejection [75] and the dominant role of Dll1/4 Notch ligands in GVHD [72, 76]. Anti-
Dll1/4 antibodies had high therapeutic activity in allograft rejection. Both anti-Dll1 and anti-Dll4 
antibodies by themselves induced significant protection, indicating that these two Notch ligands 
were involved non-redundantly in the rejection process. Combined administration of anti-Dll1 
and anti-Dll4 antibodies was the most effective strategy tested, enabling long-term engraftment 
in CD8-depleted recipients and markedly delayed rejection even in CD8-replete hosts. 
Surprisingly, systemic Dll1/4 blockade provided a higher degree of protection from allograft 
rejection than DNMAML-mediated pan-Notch inhibition in T cells. Enhanced protection was 
associated with a persistent decrease in donor-specific alloantibody titers, plasma cell numbers 
and complement deposition in the graft. These findings suggest that the therapeutic activity of 
anti-Dll1/4 antibodies is related both to their effects on T cells (preventing acute cellular 
rejection) and to their effects on the B cell response (preventing chronic rejection at least in part 
through humoral mechanisms). Furthermore, long-term protection was observed upon short-term 
Dll1/4 blockade in the peri-transplant period, similar to findings in allogeneic bone marrow 
transplantation and GVHD [72, 74]. 
Together, Dll1/4 Notch ligands play dominant roles in the regulation of alloimmunity, but the 
role of Jagged ligands remains unclear. To start addressing this question, Riella and coworkers 
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Table 1.1. Summary of published work using in vivo loss-of-function approaches to 
evaluate the role of Notch signaling in T cell alloimmunity 
A. Allograft rejection   
B. Graft-versus-host disease 
  13 
used a Jagged2-specific antibody in mouse heart allograft rejection models [81].  This antibody 
was previously shown to specifically bind Jagged2, but was suggested to facilitate forward Notch 
signaling in an in vitro coculture system through unknown mechanisms [82]. Jagged2-specific 
antibodies induced accelerated rejection in two heterotopic heart transplantation models. 
Accelerated rejection was associated with complex immunological changes, including increased 
production of IL-6 and Th2 cytokines, and increased Treg expansion. These findings suggest that 
Jagged2 can have a proinflammatory role in allograft rejection, but interpretation is challenging, 
as the biochemical impact of the Jagged2-specific antibody used in these studies is not fully 
characterized. Future work using genetic approaches and other pharmacological reagents could 
clarify the role of Jagged ligands in transplant rejection. 
Although there are differences in experimental approaches, particularly in terms of global 
Notch inhibition in T cells vs. selective systemic targeting of Notch pathway components, 
studies of allograft rejection and in vivo Notch inhibition delineate elements of an emerging 
consensus: 1) Notch signaling is a major pathway that promotes inflammation and opposes 
tolerance in allograft transplantation; 2) Notch signaling controls alloreactive T cell immunity, 
but may also regulate non-T cell subsets that contribute to the pathogenesis of organ rejection; 3) 
Targeting the Notch pathway has therapeutic potential to prevent allograft rejection, with short-
term blockade of Delta-like Notch ligands in the peri-transplant period capable of inducing long-
term effects. 
In vivo studies of Notch signaling in graft-versus-host disease 
Table 1.1B highlights the studies that employed loss-of-function approaches to interrogate 
the role of Notch signaling in GVHD [71-73, 76, 77]. Using DNMAML expression or Rbpj 
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inactivation to block all canonical Notch signals in T cells, Zhang et al. first reported major 
protective effects of Notch inhibition in mouse models of acute GVHD [71]. Notch inhibition led 
to markedly increased survival of transplant recipients. Notch-deprived alloreactive T cells 
showed decreased production of multiple inflammatory cytokines (including IFNγ, TNFα, IL-17 
and IL-4) and increased expansion of preexisting Tregs [71, 73]. Decreased cytokine production 
was observed in both CD4+ and CD8+ T cells, and was associated with features of acquired 
hyporesponsiveness in alloreactive T cells [73]. Individual T cell effector functions were affected 
to a variable extent by Notch inhibition, as in vivo T cell proliferation and expansion were 
preserved in irradiated recipients. T cell cytotoxic functions were also largely maintained in the 
absence of Notch signaling, leading to the preservation of potent graft-versus-tumor effects. 
Using a genetic strategy to inactivate the Notch1 or the Rbpj gene only in Tregs, Chatila’s group 
reported that Notch negatively regulates Treg numbers and function in vivo, and that Notch 
inhibition in Tregs alone conferred therapeutic benefits in acute GVHD [78]. Thus, Notch 
inhibition may exert beneficial immunomodulation in conventional CD4+ and CD8+ Teff as well 
as in Tregs. 
Therapeutically, γ-secretase inhibitors (GSI) were shown to be effective in a mouse model of 
alloimmune bone marrow injury [77]. However, in acute GVHD models involving lethal 
irradiation, systemic pan-Notch inhibition with GSI was poorly tolerated because of on-target 
toxicity in the gut [72]. To bypass this toxicity, the role of individual Notch ligands and receptors 
was investigated using genetic models and paralog-specific monoclonal antibodies [72, 76]. 
Notch1/Notch2 receptors and Dll1/4 Notch ligands accounted for all the effects of Notch 
signaling in alloreactive T cells during GVHD, with dominant roles for Notch1 and Dll4. Dll1/4 
blockade emerged as the most promising therapeutic approach to prevent GVHD while avoiding 
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system side effects of pan-Notch inhibition. Interestingly, transient early Dll1/4 inhibition was 
essential and sufficient to confer long-term GVHD protection [72].  Altogether, clear parallels 
are emerging between the functions of Notch signaling in acute GVHD and allograft rejection. In 
both cases, early Dll1/4-mediated Notch signals exert profound and durable pro-inflammatory 
effects, such that transient Dll1/4 inhibition provides long-lasting therapeutic benefits. 
 
Mechanistic considerations 
The molecular mechanisms of Notch action in mature T cells remain under active 
investigation. The most relevant observations are and will continue to be derived from in vivo 
experiments that evaluate physiological levels of Notch signaling in defined immunological 
contexts. Along these lines of investigations, Notch was recently reported to regulate specific 
functions of CD4+ and CD8+ T cells, including in vivo survival and metabolism, responsiveness 
to CD28-mediated costimulatory signals, and CD8+ T cell differentiation [66, 68, 70, 83-85]. An 
important overarching theme is that Notch does not appear to function as a lineage-specific 
regulator, but instead as a regulator of T cell reactivity and function. In T cell alloimmunity, 
multiple investigators observed that Notch inhibition tips the balance between inflammatory Teff 
and suppressive Treg functions (Fig. 1.3) [71, 74, 78]. Notch-deficient Teff cells appear defective 
in their production of multiple inflammatory cytokines, while Notch-deficient Tregs accumulate in 
higher absolute or relative numbers and may have enhanced suppressive ability.  The dual effects 
on both Teff and Tregs likely account for the prolonged impact of transient Notch inhibition. Of 
note, key downstream effects of Notch signaling are likely to be mediated by canonical  
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Figure 1.3. Emerging model of Notch signaling as a central regulator of alloreactivity vs. 
tolerance. 
Notch drives T cell pathogenicity during allotransplantation by enhancing pathogenic functions in effector 
T cells, while decreasing numbers and beneficial immunosuppressive functions of FoxP3+ regulatory T 
cells (Tregs). Interfering with the Notch pathway can reverse this imbalance by dampening 
proinflammatory cytokine production by Teff cells and enhancing both Treg function and numbers. 
Importantly, short-term Notch inhibition in the peri-transplant period can confer long-lasting 
immunological benefits. 
 
CSL/MAML-dependent transcriptional mechanisms [71, 78], but the functionally essential 
targets of Notch signaling in Teff and Tregs remain to be identified. 
Therapeutic implications and future directions 
Based on available preclinical data, we propose that Notch signaling is an attractive new 
therapeutic target to prevent allograft rejection. Short-term inhibition of Notch signaling exerts a 
longstanding beneficial impact by dampening the alloimmune response, highlighting the promise 
of transient Notch inhibition strategies in the peritransplant period [72, 74]. Beyond allograft 
rejection, Notch inhibition could also be beneficial in other T cell-mediated immune disorders, 
including GVHD and autoimmunity [72, 86, 87]. In practice, targeting individual Notch ligands 
and receptors with specific monoclonal antibodies currently appears to be the most promising 
therapeutic approach to target Notch signaling in alloimmune cells, while avoiding the systemic 
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side effects of pan-Notch inhibition [72, 74, 75]. As for other strategies, an important challenge 
will be to translate these findings from preclinical mouse models into more advanced preclinical 
models (e.g. non-human primates) and into humans. Given that Notch is an ancient and highly 
conserved signaling pathway, it is tempting to speculate that key features of its effects will be 
conserved, although this needs to be investigated systematically.  Advances in our understanding 
of Notch’s immunobiological effects and carefully designed translational investigations could 
unravel the full therapeutic potential of Notch inhibition in allograft rejection and other immune-
mediated disorders. 
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Chapter 2 
Fibroblastic Reticular Cells in Immunity 
Secondary lymphoid organs (SLOs), which include lymph nodes, spleen, Peyer’s patches and 
lymphoid aggregates associated with mucosal tissues, are key organizational hubs that ensure 
efficient immune responses against foreign antigens.   Rare antigen-specific cells utilize the 
unique organization and strategic location of SLOs to encounter their cognate antigens.  
Consequently, SLOs also serve as major enablers of inappropriate responses against foreign 
tissue antigens or self-antigens.   
One important feature of SLOs is their highly compartmentalized nature – antigen-responsive 
effector cells, such as T cells and B cells, are restricted to distinct microanatomical locations.  
This feature not only helps rare antigen-specific effector cells encounter their cognate antigen to 
promote their activation, but also serves as a mechanism for preventing inappropriate immune 
responses.  Much of the structural organization of SLOs is determined by nonhematopoietic 
stromal cells, which serve as the cellular backbone.  Additionally, recent literature has revealed 
that nonhematopoietic stromal cells can play active roles in immune responses.  In this chapter, I 
will review the diverse functions of stromal cells with a special focus on fibroblastic reticular 
cells (FRCs), and how they contribute to appropriate immune system function. 
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Diversity of stromal cells within SLOs 
Within SLOs, radioresistant stromal cells are a heterogeneous population, and include blood 
endothelial cells (BECs), lymphatic endothelial cells (LECs), follicular dendritic cells (FDCs), 
marginal reticular cells (MRCs), and fibroblastic reticular cells (FRCs).  These cells can be 
distinguished from each other by their anatomical location, morphology, and surface marker 
expression. 
Vascular blood endothelial cells (BECs) 
BECs play a critical role in providing SLOs with vascular support.  Among BECs, high 
endothelial venules [88] are a small subset of specialized postcapillary venules that are 
absolutely critical for the entry of naïve lymphocytes into the LN parenchyma.  HEVs 
transcytose and present key recruitment chemokines on their cell surface to attract T cells [89, 
90].  BECs can be distinguished from other SLO-resident stromal cells by their expression of the 
surface markers CD31/PECAM-1, and the lack of expression of the surface markers 
gp38/podoplanin and CD45. 
Lymphatic endothelial cells (LECs) 
LECs line the afferent and efferent lymphatic vessels that transport interstitial fluid into and 
away from LNs, respectively. Aside from facilitating the delivery of antigens, several reports 
have identified LECs as enforcers of peripheral tolerance through the cross-presentation of self-
antigen [91].  LECs can be distinguished from other SLO-resident stromal cells by their 
expression of the surface markers gp38/podoplanin, CD31/PECAM-1, and LYVE-1, and their 
lack of expression of CD45.   
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Follicular dendritic cells (FDCs) 
FDCs form the structural backbone on which B cells traffic and encounter antigen [92].  
They are important cellular sources of the B cell chemoattractant CXCL13.  During germinal 
center responses, FDCs and T follicular helper cells (Tfh) engage with maturing B cells to 
undergo positive selection of the highest affinity clones [93].  FDCs can be distinguished from 
other SLO-resident stromal cells by their expression of the surface markers gp38/podoplanin, 
CD21/35, and FcγR, and their lack of expression of CD45 and CD31/PECAM-1.  
Marginal reticular cells (MRCs) 
First identified in 2008, MRCs are physically located within the outer ridge of B cell 
follicles, underneath the subcapsular sinus [94].  Lineage tracing studies suggest that MRCs are 
precursors of FDCs, and can be induced to develop into FDCs with inflammation [95].  MRCs 
can be distinguished from other SLO-resident stromal cells by their expression of the surface 
markers gp38/podoplanin, MAdCAM-1, and RANKL, and their lack of expression of CD45 and 
CD31/PECAM-1.  
Fibroblastic reticular cells (FRCs) 
Constituting 20-50% of the stromal cells within the LN, FRCs are a heterogeneous 
population of mesenchymal origin.  Like myofibroblasts, FRCs exhibit high contractile activity, 
and generate physical tension throughout the LN.  FRCs are derived from lymphoid tissue 
inducer cells (LTo), and require lymphotoxin (LT) signaling for their appropriate development.  
FRCs can be distinguished from other SLO-resident stromal cells by their expression of the 
surface markers gp38/podoplanin and CD140α/platelet-derived growth factor receptor α, and 
their lack of expression of CD45 and CD31/PECAM-1.  Recent characterization of FRC subsets 
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have identified at least 3 different subtypes: 1) T zone FRCs; 2) Medullary FRCs; 3) Pericytic 
FRCs.  Subsets of FRCs are distinguished from each other by their anatomical location within 
the LN.  
FRCs as key structural components 
The potential structural importance of stromal cells, particularly FRCs, was first appreciated 
in anatomical studies of LN sections [96].  Silver staining identified a large network of collagen 
fibrils and extracellular matrix (ECM) that was completely ensheathed by FRCs; together, this 
structural backbone of ECM, collagen, and FRCs was termed the reticular network.  T and B 
lymphocytes were completely excluded from this ‘labyrinthine cavity,’ suggesting that FRCs 
served as a physical barrier that prevented lymphocytes from directly encountering the structural 
backbone [97].  Later work revealed that FRCs play a far more active role than simply as 
physical barriers.  Immunofluorescence staining with the monoclonal antibody ER-TR7, which 
binds a yet unidentified epitope on FRCs, demarcated the LN into four major subanatomic 
regions: 1) Subcapsule-associated reticular network; 2) B cell-associated reticular network; 3) T 
cell-associated reticular network; 4) Medullary reticular network [98].  ER-TR7 staining also 
enabled the first identification of the cortical ridge as a unique anatomical structure that was 
highly enriched for both DCs and HEVs.   
FRCs form conduits for the rapid transit of antigen and chemokines 
Elegant studies with fluorescently labeled model antigen determined that dendritic cells 
acquire subcutaneously delivered antigen in two temporally distinct phases [99].  While the first 
wave occurs within minutes after antigen injection, a second wave of antigen acquisition occurs 
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4-14 hours later.  The earlier phase of antigen delivery is restricted to smaller antigens, as only 
low molecular weight particles (<70 kDa) are able to enter the LN [100].   
3D reconstruction studies of LN sections immediately after subcutaneous delivery of 
fluorescently labeled tracers revealed that the FRC-ensheathed reticular network is responsible 
for the first delivery phase of antigen [101].  Upon entering the sinuses of the draining lymph 
node, antigen was found to rapidly travel through a multilayered conduit that consisted of a 
collagen I/collagen III core surrounded by an ECM layer of fibrillin-1/fibrillin-2, a basement 
membrane, and a layer of FRCs. Fluorescently labeled tracer was restricted to the luminal side of 
the basement membrane, suggesting that it was self-contained within the conduit.  Systematic 
immunofluorescence staining of the conduit’s basement membrane revealed that it consisted of 
laminin 10, laminin 8, nidogen, perlecan, collagen IV, and fibronectin.  Immature CD11b+ 
resident DCs, but not migratory mature DCs, closely associated with the basement membrane of 
the conduits through β1 integrin-mediated adhesion to laminin 10/laminin 8.  Thus, it was 
concluded that FRCs form a self-enclosed conduit that delivers antigen to uniquely positioned 
resident DCs, allowing for rapid antigen acquisition. 
FRCs as scaffolds for naïve T cell trafficking 
Two-photon excitation microscopy led to the direct visualization of mature T trafficking 
within SLOs [102, 103].  In these studies, while naïve T cells were generally found to move in a 
random fashion, they often displayed tendencies to abruptly change direction.  Thus, it was 
hypothesized that T cells were being “guided” along scaffolds, perhaps along the reticular 
network formed by FRCs. 
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Consistent with this hypothesis, quantification of images from fixed tissue sections 
demonstrated that naïve T cells nearly always colocalized with the FRC-specific antigen ER-TR7 
[92].  Furthermore, intravital imaging studies of popliteal LNs from live BM chimeras that 
expressed GFP only within nonhematopoietic tissues (WTàUBI-GFP) revealed that 
fluorescently labeled T cells actively crawled along the fibers of GFP+ FRCs.  Notably, there was 
a very high correlation (>90%) between changes in T cell direction and corresponding changes in 
FRC fiber direction.  Thus, it was concluded that FRC fibers provide a directional scaffold along 
which naïve T cells migrate.  
In the same study, confocal imaging of static sections from WTàUBI-GFP chimeras 
identified a population of desmin+ GFP+ ER-TR7+ FRCs that completely surrounded PNAd+ 
HEVs.  Thus, it was hypothesized that this specialized subset of FRCs was important for 
regulating the entry of lymphocytes into the LN parenchyma via the bloodstream.  Indeed, 
adoptively transferred naïve T cells traversed across HEVs to enter the LN parenchyma via 
discrete spaces between adjacent FRCs.  Interestingly, these “exit ramps” were not uniformly 
distributed throughout the length of the blood vessel, but instead located in fixed locations.  
Thus, it was concluded that FRCs not only provide guidance cues for trafficking within the 
lymph node, but also actively regulate the entry of naïve T cells into the LN cortex by forming 
discrete, fixed access points. 
FRCs as important sources of chemokines and cytokines 
CCL19/Epstein-Barr virus-induced molecule-1 ligand chemokine (ELC) and 
CCL21/Secondary Lymphoid organ chemokine (SLC) recruit naïve lymphocytes and DCs into 
SLOs through ligation of their cognate receptor, CCR7.  Paucity of lymph node T cells (plt)/plt 
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mice, which harbor autosomal recessive mutations in both ccl19 and ccl21, display defective 
migration of lymphocytes and DCs into SLOs, leading to high susceptibility to viral infections 
[104].  Early in situ hybridization studies identified gp38+ radioresistant stromal cells as the 
major sources of both ccl19 and ccl21 [105].  Consistent with this notion, transfer of WT BM 
into plt/plt mice was insufficient to rescue the defects in expression of either chemokine.  Thus, 
these data identified an essential role for FRCs in the recruitment of lymphocytes and DCs into 
the LN.  Subsequent studies demonstrated that FRCs also secrete the prosurvival cytokine IL-7 
to ensure naïve T cell homeostasis [106].  Inhibition of naïve T cell access to LNs with anti-
CD62L neutralizing antibodies resulted in decreased T cell numbers in the spleen and blood.  
Furthermore addition of ex vivo-isolated FRCs to naïve T cell cultures enhanced their survival in 
an IL-7/Ccl19-dependent manner. 
Unbiased transcriptional profiling confirmed that FRCs expressed high levels of chemokines 
and ECM components [107].  Consistent with the previously mentioned functional studies, FRCs 
produced significantly high levels of for ccl19, ccl21a, and il7 transcripts.  FRCs also expressed 
high levels of vascular trophic factors, metalloproteases, and cell adhesions molecules.  
Interestingly, in vivo exposure of FRCs to an active immune response upregulated many 
components of the MHC class II presentation machinery, suggesting they could be involved in 
antigen processing during inflammatory conditions.  FRCs transcriptionally upregulated both 
alpha and beta chains of MHC class II and several intracellular components of the antigen 
presentation pathway (invariant chain, cathepsin S, H2-DM).  FRCs also upregulated surface 
levels of MHC class II.   
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FRCs mediate contraction and expansion of the lymph node  
Upon initiation of an immune response, the lymph node must expand and swell to 
accommodate the influx of new immune cells.  This expansion is mediated by two general 
mechanisms: 1) proliferation and expansion of FRCs [108]; 2) abrogation of FRC contractile 
activity [109, 110]. Mechanistically, the contractile activity of FRCs is controlled by 
receptor/ligand interactions between FRC-derived podoplanin/gp38 and DC-derived C-lectin 
receptor CLEC-2.  During homeostatic conditions, the low availability of CLEC-2 ligand allows 
for unhindered podoplanin signaling, resulting in the recruitment and phosphorylation of the 
ezrin/radixin/moesin (ERM) complex.  Phosphorylation of ERM results in the phosphorylation 
of myosin light chain and subsequent activation of RhoA to promote contractile activity.  During 
inflammatory conditions, DCs upregulate CLEC-2, and thus inhibit the signaling capability of 
podoplanin.  Consequently, ligation of podoplanin by CLEC-2 inhibits ERM phosphorylation 
and RhoA-mediated contractile activity.  Accordingly, genetic inactivation of podoplanin on 
FRCs or clec2 on DCs results in persistent LN contractile activity, and subsequent failure to 
accommodate the influx of new cells.  Therefore, direct signaling between FRCs and DCs drives 
the contractile activity of LN.  
FRCs as enforcers of peripheral tolerance 
Tolerance to self-antigens, or the decision to not undergo a full inflammatory response, is an 
important aspect of immunity.  Immune tolerance is enforced through two general mechanisms, 
first through negative selection of autoreactive developing T cell clones within the thymus 
(termed central tolerance), and second through deletion or disabling of self-antigen responders 
that escape negative selection within the thymus (termed peripheral tolerance).  Maintenance of 
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tolerance to self-antigen is of paramount importance, as failure to enforce central or peripheral 
tolerance results in autoimmunity and exaggerated immune responses.   During peripheral 
tolerance of CD8+ cells, self-antigen responsive CD8+ T cells proliferate in response to antigen 
initially, but undergo clonal deletion through apoptotic mechanisms. 
It was widely believed that circulating tolerogenic DCs played a key role in enforcing 
peripheral tolerance.  However, this notion was challenged by a series of in vivo experiments in a 
mouse model of peripheral tolerance, in which ovalbumin (OVA) is expressed by intestinal 
epithelial cells (IECs) within the small bowel (iFABP-tOVA) [111].  When transferred into 
iFABP-OVA mice, OVA-specific TCR transgenic CD8+ OT-I cells proliferated not only within 
the site of antigen expression (mesenteric LN, inguinal LN), but also in the periphery (inguinal, 
brachial, renal LNs).  Interestingly, inhibition of T cell egress with the sphingosine 1-phosphate 
agonist FTY720 did not prevent the detection of proliferated OT-I cells in the periphery, thus 
ruling out T cell migration as an explanation and rather suggesting that OVA was presented in 
the periphery by an alternative cell source.  This cellular source of OVA antigen was 
nonhematopoietic, as bone marrow (BM) chimeras lacking MHC I specifically within 
hematopoietic cells (but not nonhematopoietic cells) remained capable of promoting OT-I 
proliferation in the periphery.  Careful quantitative PCR (qRT-PCR) analysis of various LN-
resident nonhematopoietic cell subsets, including FRCs, BECs, and LECs, demonstrated that 
FRCs expressed not only OVA, but also other self-antigens. Indeed, in vitro coculture of FRCs 
from iFABP-tOVA mice with OT-I T cells, in the absence of classical APCs such as DCs, 
resulted in their intense proliferation and upregulation of CD25 [112]. 
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FRCs as negative regulators of T cell proliferation 
In 2011, three groups independently published the surprising finding that FRCs suppress T 
cell proliferation in a dose-dependent manner when added to T cell/antigen-pulsed DC cocultures 
[113-115].  These results were quite surprising, as it had been previously published that FRCs 
themselves were capable of stimulating T cell proliferation in the absence of classical APCs.  
Similar suppressive effects were observed when FRCs were cultured with CD3/CD28-activated 
OT-I cells.  Suppression by FRCs occurred in an IFNγ-dependent manner, as genetic deletion of 
IFNγR within FRCs abrogated their ability to suppress OT-I proliferation.  IFNγ signaling-
mediated suppression occurred independently of the classic inhibitory molecule PD-L1, and 
instead was dependent on the production of NOS2 and COX1/2-dependent factors by FRCs.  
Pharmacologic inhibition of NOS2 or COX1/2, but not inhibition of IDO-1 or Arg1, impaired the 
ability of FRCs to suppress OT-I proliferation in vitro.  Consistent with this notion, mice 
genetically deficient in nos2 engendered exuberant immune responses to antigen.  Taken 
together, these data suggested a model in which FRCs, upon sensing T cell activation through 
their production of IFNγ, upregulate soluble inhibitory factors to serve as a brake for excessive T 
cell activation. 
FRC niches as nonredundant sources of Delta-like Notch ligands during Notch-
dependent immune responses 
In 1999, it was reported that Mx1-Cre-mediated genetic inactivation of notch1 in 
hematopoietic tissues of neonatal mice resulted in a cell-autonomous block in T cell 
development (see Chapter 1, “Overview of Notch signaling” for more detailed review of 
Notch signaling within the hematopoietic system) [27].  This was the first study that identified a 
  28 
role for mammalian Notch1 within the hematopoietic system.  Mice that lacked notch1 within 
their hematopoietic tissues displayed a decrease in the frequencies of single positive (SP) and 
double positive [79] developing T cells, with a concomitant increase in the frequency of B220+ B 
cells.  Other hematopoietic lineages were unaffected.  Subsequently, it was identified that while 
overexpression of either Delta-like1 (Dll1) or Delta-like4 (Dll4) Notch ligands within OP9 
stromal cells could sustain T cell development in vitro [116, 117], only Dll4 was expressed 
within thymic epithelial cells.  Genetic inactivation of Dll4 with the thymic epithelial cell (TEC)-
restricted Cre recombinase Foxn1-Cre phenocopied the thymic defect that was first identified in 
mice with conditional notch1 inactivation.  Thus, it was concluded that developing thymocytes 
received their Notch1-mediated signals exclusively from Dll4-expressing nonhematopoietic 
Foxn1+ TECs [34, 118].   
Similar loss-of-function studies subsequently identified three other hematopoietic cell types 
that were dependent on Notch signaling for their development and/or maintenance: 1) splenic 
marginal zone B cells (MZBs), which exclusively utilized Notch2-mediated signals from Dll1 
[117, 119]; 2) splenic Esamhi CD11c+ DCs, which exclusively utilized Notch2-mediated signals 
from an unknown Notch ligand [120, 121]; 3) spleen/LN-resident Tfh cells, which received their 
Notch signals through both Notch1 and Notch2 receptors from an unknown Notch ligand [122]. 
Seminal work from the Radtke and Luther labs determined the identity and cellular source of 
Notch ligands that were necessary for the development/maintenance of the three aforementioned 
Notch-dependent hematopoietic cell types [123].  To this end, Notch ligands were conditionally 
inactivated with tissue-specific Cre recombinases in a systematic fashion.  Although DCs and 
BECs had been previously reported to express high levels of Delta-like Notch ligands [51, 124, 
125], conditional inactivation of Dll1 or Dll4 with the DC-specific Itgax-Cre or the BEC-specific 
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Pdgfβ-CreERT had no impact on the development of MZBs, Esamhi DCs, or Tfh cells.  
Additionally, BM chimeras that lacked Dll1, Dll4, Jag1, or Jag2 specifically within their 
hematopoietic tissues (TgMx1-Cre+;Dll1Δ/Δ à CD45.1, TgMx1-Cre+;Dll4Δ/Δ à CD45.1, TgMx1-
Cre+;Jag1Δ/Δ à CD45.1, TgMx1-Cre+;Jag2Δ/Δà CD45.1) remained proficient in generating robust 
Tfh responses.  Instead, all three hematopoietic Notch-dependent cell types were found to 
encounter their Notch ligands on secondary lymphoid organ-resident mesenchymal stromal cells, 
which could be selectively targeted with a Ccl19-Cre BAC transgene [126].   Conditional 
deletion of Dll1 with Ccl19-Cre resulted in complete loss of MZB and Esamhi DCs, while 
conditional deletion of Dll4 with Ccl19-Cre resulted in markedly decreased Tfh frequencies.  
Consistent with these findings, TgCcl19-cre+;Dll1Δ/Δ mice were partially defective in supporting 
antigen-dependent CD4+ T cell proliferation due to their lack of Esamhi DCs, while TgCcl19-
cre+;Dll4Δ/Δ mice displayed blunted germinal center responses when challenged with infectious 
stimuli due to their lack of Tfh cells. 
Immunofluorescence microscopy, flow cytometry, and qRT-PCR analysis of Dll1 and Dll4 
expression within secondary lymphoid tissues of TgCcl19-cre+;ROSA26eYFP reporter mice 
identified three major secondary lymphoid-resident stromal cell types as key cellular sources of 
Notch ligands – FRCs, MRCs, and FDCs.  Importantly, Ccl19-Cre displayed no activity within 
hematopoietic tissues or BECs.  Thus, these seminal studies identified a completely unexpected, 
novel role for nonhematopoietic LN/spleen-resident stromal cells, in particular FRCs, in 
fostering efficient immune responses through the delivery of critical Notch signals to developing 
immune cells.  Mice that lacked Delta-like Notch ligand expression within their mesenchymal 
stromal cells were unable to form MZBs, Esamhi DCs, and Tfh cells. 
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FRCs in allotransplantation 
As the field of experimental GVHD has focused much of its attention on the role of 
hematopoietic cells in mediating disease, very little is known about the role of FRCs during 
allotransplantation.  Recently, it was reported that FRCs are cellular targets of allogeneic T cells 
during GVHD [127].  In both major and minor-mismatched CD8-dependent models of GVHD, 
several nonhematopoietic stromal cell types, including CD157+ FRCs and PNAd+ HEVs, were 
selectively depleted from LNs within 14 days post-transplantation.  This effect was independent 
of irradiation, and was dependent on FasL-mediated cytotoxicity.  Functionally, mice that 
received allogeneic transplants displayed long-term humoral defects in response to immune 
challenge.  Thus, these results identified LN-resident FRCs as an additional cellular target of 
GVHD.   
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Chapter 3 
Fibroblastic niches prime T cell alloimmunity through Delta-like Notch 
ligands2 
Abstract 
Alloimmune T cell responses induce graft-versus-host disease (GVHD), a serious complication 
of allogeneic bone marrow transplantation (allo-BMT). Although Notch signaling mediated by 
Delta-like1/4 (Dll1/4) ligands emerged as a major regulator of GVHD pathogenesis, little is 
known about the timing of Notch signals and the cellular source of Notch ligands after allo-
BMT. Here, we show that Dll1/4-mediated Notch signals are delivered to donor T cells during a 
critical 48-hour window after transplantation. Surprisingly, stromal but not hematopoietic cells 
were the essential source of Notch ligands. Selective Dll1/Dll4 inactivation in host chemokine 
Ccl19+ fibroblastic reticular cells prevented GVHD. Neither T cell recruitment nor initial 
activation were affected, indicating selective effects of stromal Dll1/4 ligands on alloimmune 
tolerance and reactivity. Our results reveal a previously unrecognized Notch-mediated 
                                                            
2 Taken from:  
Chung, J., Ebens C.L., Radojcic, V., Perkey E., Koch U., Scarpellino, L., Tong, A., Allen, F., 
Wood, S., Feng, J., Friedman A., Granadier, D., Tran, I.T., Chai, Q., Onder, L., Yan M., Reddy 
P., Blazar, B.R., Huang, A.Y., Brennan, T.V., Bishop, D.K., Ludewig, B., Siebel, C.W., Radtke, 
F., Luther, S.A., Maillard, I. Fibroblastic niches prime T cell allimmunity through Delta-like 
Notch ligands. Submitted 
  32 
immunopathogenic role for stromal cell niches in secondary lymphoid organs, thus defining a 
new framework of early cellular and molecular interactions that regulate T cell alloimmunity. 
Introduction 
Allogeneic bone marrow transplantation (allo-BMT) can cure hematological malignancies 
and other blood disorders. However, alloimmune T cell responses arising against foreign tissue 
antigens can trigger major complications after allo-BMT, such as graft-versus-host-disease 
(GVHD) [5, 128]. At the onset of GVHD, donor T cells are exposed to host tissue alloantigens in 
a highly inflammatory environment, inducing potent T cell immunoreactivity and subsequent 
pathogenicity. Current GVHD prophylactic and therapeutic strategies act through global 
immunosuppression, and thus diminish both beneficial and detrimental aspects of T cell 
alloreactivity. Efforts to develop new selective therapies to dampen GVHD have focused on 
early microenvironmental signals to donor alloreactive T cells [129]. Many of these signals, 
which include alloantigens, costimulatory ligands and local inflammatory mediators, have been 
assumed to derive from hematopoietic antigen-presenting cells (APCs). However, recent work 
demonstrated that CD4+ T cell-mediated alloresponses can occur in the absence of hematopoietic 
APCs as a source of alloantigens [130-132], suggesting that our current understanding of key 
early cellular and molecular events that drive donor T cell-mediated GVHD is incomplete. 
The Notch pathway has emerged as a new attractive therapeutic target to control deleterious 
effects of T cell alloimmunity [71-75, 77, 78]. Notch signaling is a conserved cell-to-cell 
communication pathway mediated by interactions between Notch1-4 receptors and its ligands 
Delta-like1/3/4 (Dll1/3/4) or Jagged1/2 [20, 21]. During GVHD, Dll1/4 ligands in the host 
engage Notch1/2 receptors in T cells, and transient systemic blockade of Dll1/4 Notch ligands 
with neutralizing antibodies results in long-term protection from GVHD [72]. Despite the central 
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role of Notch signaling in alloreactivity, the timing of critical Notch signals, the cellular source 
of Notch ligands and the microanatomical context in which alloreactive T cells are exposed to 
Notch signaling in vivo remain unknown. 
Early studies showed that hematopoietic APCs such as dendritic cells (DCs) can express Dll1 
and Dll4 ligands in a Toll-like receptor (TLR)-inducible manner [51, 124]. These observations 
led to the widely accepted concept that hematopoietic APCs can simultaneously deliver antigen 
and Notch ligands to modulate T cell function. In vitro studies supported this model, as TLR 
agonist-stimulated antigen-pulsed DCs induced naïve T cells to differentiate in a Notch-regulated 
manner [51, 53]. Similarly, a subpopulation of CD11c+Dll4hi DCs was capable of delivering 
Notch signals to alloreactive T cells in mixed lymphocyte reactions when purified from GVHD 
animal models [76]. However, the in vivo relevance of APC-derived Notch signals has not been 
rigorously tested, and their importance has been inferred indirectly based on their capacity to 
modulate T cell responses in vitro. Non-hematopoietic cells also express Notch ligands in 
multiple contexts, including in primary and secondary lymphoid organs (SLOs). In the thymus, 
Foxn1+ thymic epithelial cells act as non-redundant transducers of Dll4-mediated signals during 
T cell development [34, 118, 133]. Blood and lymphatic endothelial cells (BECs/LECs) express 
high levels of Dll1 and Dll4 [125, 134-137]. Finally, genetic studies identified fibroblastic 
reticular cells (FRCs) in SLOs as non-redundant sources of Dll1-mediated Notch signals to 
marginal zone B cells and Esamhi DCs, as well as Dll4-mediated signals to follicular helper T 
cells [123]. Thus, multiple cellular sources have the potential to deliver Notch signals to T cells 
in vivo after allo-BMT, making it unclear if critical signals are delivered in a defined 
microanatomical niche, and by hematopoietic or stromal cells. 
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To address these questions, we employed a combination of systemic neutralizing antibodies 
and loss-of-function genetics to interrogate the in vivo spatial and temporal requirements for 
Dll1/4-mediated Notch signaling during GVHD. Surprisingly, we found that all essential Notch 
signals were delivered to incoming T cells within 2 days after allo-BMT, and that both donor and 
host hematopoietic cells were dispensable as a source of Notch ligands that drives acute GVHD. 
In contrast, a defined subset of non-hematopoietic FRCs lineage-traced with a Ccl19-Cre 
transgene functioned as the essential non-redundant cellular source of Delta-like Notch ligands 
after allo-BMT. Interference with Notch ligands in FRCs had selective effects on T cell 
alloreactivity and did not impair other functions of these cells in immune homeostasis. These 
findings change our understanding of the key early cellular and molecular events that condition 
the outcome of T cell alloimmunity. In addition, they pave the way towards development of 
targeted therapeutic approaches to block Notch signaling and other stromal niche-derived 
pathogenic signals in GVHD and other T cell-mediated immune disorders. 
Results 
Early Delta-like1/4-mediated Notch signals drive T cell alloreactivity during acute GVHD 
To understand the temporal requirement for Notch signaling after allo-BMT, we used 
neutralizing antibodies against Dll1 and Dll4 Notch ligands in an irradiation-dependent major 
histocompatibility complex (MHC)-mismatched mouse allo-BMT model (Fig. 3.1A). A single 
injection of Dll1 and Dll4-neutralizing antibodies before allo-BMT was sufficient to confer long-
term protection from GVHD lethality and morbidity, while decreasing production of T cell 
proinflammatory cytokines and expanding FoxP3+ regulatory T cells (Tregs) (Fig. 3.1B-D, Fig. 
3.2A). In contrast, delayed initiation of antibody treatment by only two days resulted in loss of 
clinical protection, persistent IFNγ and TNFα production, and no increase in Tregs. Dll1/4 
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blockade inhibited Notch target gene expression in donor-derived alloreactive T cells (Fig. 3.2B-
C). These data identify an early pulse of Notch signaling delivered within two days after allo-
BMT that programs T cells to a pathogenic state of reactivity. 
 
Figure 3.1. An early pulse of Notch signaling is critical to drive pathogenic T cell 
alloreactivity after bone marrow transplantation 
A. Dosing schedule of systemic neutralizing antibodies against Dll1 and Dll4 Notch ligands. B. Survival, 
GVHD score and weight of lethally irradiated (8.5 Gy) BALB/c mice transplanted with 5x106 T cell-
depleted (TCD) B6 BM or 5x106 TCD B6 BM + 5x106 allogeneic B6 splenocytes. Isotype control vs. 
anti-Dll1/4 antibodies were injected i.p, as shown in A (n = 10 mice/group). C. Intracellular cytokine 
production by donor CD4+ T cells after anti-CD3/CD28 restimulation at day 6 post-transplantation (n = 5 
mice/group). D. Intracellular FoxP3 in donor CD4+ T cells at day 6 (n = 5 mice/group). *P<0.05, 
**P<0.01, ***P<0.001. Data are representative of at least 4 experiments, with error bars indicating SD. 
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Figure 3.2. Impact of Notch blockade on donor CD8+ proinflammatory cytokine 
production and Notch target gene expression 
A, Detection of intracellular cytokines in donor CD8+ T cells after anti-CD3/anti-CD28 restimulation at 
day 6 post-transplantation (flow cytometry) (n = 5 mice/group). B, Experimental strategy and flow 
cytometry plots to isolate alloreactive donor CD4+ and CD8+ T cells at day 1.75 post-transplantation. 
Syngeneic BALB/c and allogeneic B6 splenocytes were simultaneously labeled with CFSE and co-
injected into lethally irradiated (8.5 Gy) BALB/c mice. Divided CFSElow B6 cells identified alloreactive T 
cells and were sort-purified. C. Abundance of Dtx1 and Hes1 Notch target gene transcripts (qRT-PCR) in 
sort-purified donor-derived CFSElow CD4+ and CD8+ T cells (n = 6 mice/group). Cell isolation was 
performed as described in (B). Data are representative of at least 4 experiments, with error bars indicating 
SD. 
 
Donor and host hematopoietic cells are dispensable sources of Notch ligands during GVHD 
The early window of sensitivity to Notch inhibition suggested that T cells might receive 
Notch signals from residual host hematopoietic antigen-presenting cells (APCs), which can 
express both alloantigens and Notch ligands [51, 53, 70, 76, 84, 138]. To test if hematopoietic 
APCs were responsible for delivering Notch signals to donor alloreactive T cells, we generated 
bone marrow (BM) chimeras lacking Dll1/4 only in hematopoietic cells with poly(I:C)-induced 
TgMx1-cre+;Dll1Δ/Δ;Dll4Δ/Δ BM (designated as Dll1Δ/Δ;Dll4Δ/Δ→B6-CD45.1) (Fig. 3.3A). This 
strategy led to efficient Cre-mediated recombination and high donor chimerism in all 
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hematopoietic APCs (Fig. 3.3B-C). Allo-BMT into Dll1Δ/Δ;Dll4Δ/Δ→B6-CD45.1 chimeras as 
compared to control BM chimeras did not protect from GVHD mortality or morbidity (Fig. 
3.3D). In contrast, systemic antibody-mediated Dll1/Dll4 blockade protected both 
Dll1Δ/Δ;Dll4Δ/Δ→B6-CD45.1 and control BM chimeras from GVHD lethality. Consistent with 
persistent exposure to Dll1/4 ligands in these mice, donor-derived T cells expressed equivalent 
amounts of Notch target gene transcripts in Dll1Δ/Δ;Dll4Δ/Δ→B6-CD45.1 and control chimeras, 
but transcript abundance remained sensitive to systemic anti-Dll1/4 antibodies (Fig. 3.3E). Thus, 
host hematopoietic cells were dispensable as a source of Notch ligands after allo-BMT.  
To rule out redundant Dll1/4 expression in donor and host hematopoietic cells, we 
backcrossed TgMx1-cre;Dll1f/f;Dll4f/f mice to the BALB/c background, and generated BM chimeras 
with poly(I:C)-induced TgMx1-cre+;Dll1Δ/Δ;Dll4Δ/Δ donors (Dll1Δ/Δ;Dll4Δ/Δ→BALB/c) (Fig. 3.4A). 
Transplantation of Dll1Δ/Δ;Dll4Δ/Δ→B6-CD45.1 donor cells into Dll1Δ/Δ;Dll4Δ/Δ→BALB/c 
recipients (designated as Dll1Δ/Δ;Dll4Δ/Δ→Dll1Δ/Δ; Dll4Δ/Δ) had no impact on T cell cytokine 
production and Treg frequency (Fig. 3.4B-D), despite sensitivity to systemic Dll1/Dll4 blockade. 
Donor-derived T cells from Dll1Δ/Δ;Dll4Δ/Δ→Dll1Δ/Δ;Dll4Δ/Δ recipient mice retained abundant 
Notch target gene transcripts (Fig. 3.4E). Therefore, both donor and host hematopoietic cells 
were dispensable sources of Dll1/4 Notch ligands during GVHD. 
Ccl19+ stromal cells are critical sources of Notch ligands during GVHD 
Among multiple radioresistant non-hematopoietic cells that express Notch ligands in SLOs, 
FRCs act as a non-motile source of Notch ligands to immune cells in steady-state conditions 
[123]. To assess the importance of these cells during allo-BMT, we conditionally inactivated  
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Figure 3.3. Host hematopoietic cells are dispensable as cellular sources of Delta-like1/4 
Notch ligands in acute GVHD 
A. Experimental strategy. Bone marrow (BM) chimeras were generated via transplantation of syngeneic 
B6-CD45.2+ poly(I:C)-induced TgMx1-cre– littermate controls or TgMx1-cre+;Dll1Δ/Δ;Dll4Δ/Δ BM into irradiated 
B6-CD45.1 recipients. After reestablishment of steady-state hematopoiesis 12 weeks later, BM chimeras 
were subjected to a second syngeneic or allogeneic transplant, with or without systemic anti-Dll1/4 
blockade. B. Quantification of Dll1 and Dll4 inactivation in sort-purified Gr1+CD11b+ blood myeloid 
cells from BM chimeras 12 weeks after transplantation (PCR). In this particular experiment, control BM 
chimeras were generated from poly(I:C)-induced TgMx1-cre–;Dll1fl/+;Dll4fl/+ donor mice. Separate lanes 
represent individual mice. C. Donor chimerism (frequency of CD45.2+ donor cells) in indicated spleen 
populations 12 weeks after transplantation. MΦ, macrophage; DC, dendritic cell; pDC, plasmacytoid DC. 
D. Survival and weight loss of lethally irradiated (11 Gy) BM chimeras transplanted with 8x106 TCD BM 
+ 30x106 B6 splenocytes (syngeneic control) or 30x106 allogeneic BALB/c splenocytes (allo-BMT). 
Isotype control or anti-Dll1/4 antibodies were injected i.p. on days 0, 3, 7, 10 (n = 10 mice/group). E. 
Abundance of Dtx1 Notch target gene transcripts (qRT-PCR) in sort-purified donor CD4+ T cells and 
CD8+ cells at day 6 (n = 5 mice/group). *P<0.05, **P<0.01. Data are representative of at least 2 
experiments, with error bars indicating SD. 
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Figure 3.4. Both donor and host hematopoietic cells are dispensable as cellular sources of 
Delta-like Notch ligands 
A, Experimental strategy. BALB/c bone marrow (BM) chimeras were generated by syngeneic 
transplantation of BALB/c poly(I:C)-induced control or TgMx1-cre+;Dll1Δ/Δ;Dll4Δ/Δ  T cell-depleted (TCD) 
BM into irradiated BALB/c recipients (with T cell depletion performed to remove preexisting mature T 
cells that may escape Mx1-Cre-mediated target gene excision). B6 BM chimeras were generated by 
syngeneic transplantation of B6 poly(I:C)-induced control or TgMx1-cre+;Dll1Δ/Δ;Dll4Δ/Δ BM into irradiated 
B6-CD45.1 recipients. 5x106 TCD BM + 5x106 allogeneic splenocytes from B6 BM chimeras were 
transplanted into lethally irradiated (8.5 Gy) BALB/c BM chimeras. Recipient BALB/c BM chimeras 
were injected i.p. with isotype control or anti-Dll1/4 antibodies. B. Intracellular cytokines in donor CD4+ 
after anti-CD3/anti-CD28 stimulation at day 7 post-transplantation (n = 5 mice/group). C. Intracellular 
FoxP3 in donor CD4+ T cells at day 7 post-transplantation (n = 5 mice/group). D. Intracellular cytokines 
in donor CD8+ T cells after anti-CD3/anti-CD28 stimulation at day 7 post-transplantation (n = 5 
mice/group). E. Abundance of Dtx1 Notch target gene transcripts (qRT-PCR) in sort-purified donor CD4+ 
T cells or donor CD8+ T cells at day 7 post-transplantation (n = 5 mice/group). *P<0.05, **P<0.01. Data 
are representative of at least 3 experiments, with error bars indicating SD. 
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Dll1 and Dll4 with Ccl19-Cre (thereafter TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ) [126, 139, 140]. After allo- 
BMT, Ccl19-Cre lineage traced FRCs and a small fraction of LECs, but not BECs or any 
hematopoietic cells, including professional APCs (Fig. 3.5A, Fig. 3.6A-B). TgCcl19-
cre+;Dll1Δ/Δ;Dll4Δ/Δ mice were highly protected from GVHD lethality and morbidity (Fig. 3.5B). 
Markedly fewer donor T cells from TgCcl19-cre+;Dll1Δ/ΔDll4Δ/Δ recipients produced 
proinflammatory cytokines, as observed with systemic Dll1/4 blockade (Fig. 3.5C, Fig. 3.7). 
Notch target gene transcripts were profoundly decreased in donor-derived T cells isolated from 
TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ recipients (Fig. 3.5D). T cell cytokine production was preserved after 
allo-BMT into TgCcl19-cre+;Dll1+/+;Dll4+/+ recipients, ruling out Cre toxicity (Fig. 3.8). Thus, 
Ccl19-Cre-expressing FRCs were the dominant source of Dll1/Dll4 Notch ligands encountered 
in vivo by donor T cells after allo-BMT. 
Genetic inactivation of Dll1/4 ligands within Ccl19+ stromal cells preserves immune 
homeostasis and classical FRC functions 
FRCs provide survival cues to naïve T cells [106], form conduits for antigen trafficking 
[101], and support the overall SLO infrastructure [97, 141]. Physical loss of FRCs disrupts 
immune homeostasis, leading to profoundly impaired immune responses [139]. To determine if 
these FRC functions were preserved in TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice, we studied these mice 
during steady-state and in the peri-transplant period. SLOs from unirradiated TgCcl19-
cre+;Dll1Δ/Δ;Dll4Δ/Δ mice had normal lymphocyte numbers, naïve/memory T cell distribution and 
Il7 expression in FRCs (Fig. 3.9A-D). After allo-BMT, normal numbers of donor T cells were 
recovered upon Dll1/4 inactivation in FRCs, showing no impact on T cell homing (Fig. 3.10A). 
Donor T cell proliferation was maintained in TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ recipients (Fig. 3.10B,E), 
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Figure 3.5. Ccl19-Cre+ lineage-traced stromal cells are the critical cellular source of Delta-
like1/4 Notch ligands during acute GVHD 
A. eYFP expression in LN-resident fibroblastic reticular cells (FRCs), lymphatic endothelial cells (LECs), 
blood endothelial cells (BECs), macrophages (MΦ), conventional DCs (cDCs), and plasmacytoid DCs 
(pDCs) from lethally irradiated TgCcl19-cre+;ROSA26eYFP mice receiving allogeneic BALB/c splenocytes. 
LNs were collected at day 1.5 post-transplantation. B. Survival, GVHD score and weight of lethally 
irradiated (12 Gy) control TgCcl19-cre– or TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice that were transplanted with 10x106 
TCD BM only or 10x106 TCD BM + 20x106 allogeneic BALB/c splenocytes. Isotype control or anti-
Dll1/4 neutralizing antibodies were injected i.p. on days 0, 3, 7, and 10 (n = 10 mice/group). C. 
Intracellular cytokines in donor CD4+ cells after anti-CD3/CD28 restimulation  at day 6 (n = 5 
mice/group). D. Abundance of Dtx1 and Hes1 Notch target gene transcripts in donor CD4+ T cells sort-
purified from TgCcl19-cre–+ isotype control, TgCcl19-cre–+ anti-Dll1/4 or TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ recipient 
mice at day 2 post-transplantation (n = 5 mice/group). *P<0.05, **P<0.01, ***P<0.001. Data are 
representative of at least 5 experiments, with error bars indicating SD. 
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Figure 3.6. Gating strategy for flow cytometric analysis of lymph node stromal cells and 
hematopoietic antigen-presenting cells post-irradiation 
Peripheral LNs (cervical, brachial, axial, brachial) from lethally irradiated recipient (12 Gy) mice 
receiving allogeneic BALB/c splenocytes were enzymatically digested into a single cell suspension (see 
Materials and Methods) and stained for flow cytometric analysis. A. FRCs were identified as CD45–
podoplanin+CD31–, LECs as CD45–podoplanin+CD31+, and BECs as CD45–podoplanin–CD31+. B. 
Macrophages were identified as F4/80+CD11b+, cDCs as CD45+CD11c+MHCIIhi, and pDCs as 
CD45+PDCA1+B220int. LNs were collected at day 1.5 post-transplantation. Data are representative of at 
least 4 experiments. 
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or only mildly decreased at early time points for CD4+ T cells (Fig. 3.10B). Donor CD4+ and 
CD8+ T cells normally upregulated the early activation markers CD44 (Fig. 3.10C,D) and CD69 
(not shown). CD25 was decreased in TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ hosts (Fig. 3.10C,D), consistent 
with reports that Notch can regulate Il2ra expression in T cells [83, 85, 142]. Altogether, Dll1/4 
loss in FRCs maintained T cell recruitment and initial activation, consistent with preservation of 
classical FRC functions but selective loss of Dll1/4-mediated instructive signals to incoming T 
cells. 
 
Irradiation rapidly alters the microanatomy of SLOs 
To assess the impact of allo-BMT on SLO organization with respect to Ccl19+ FRCs, we 
studied TgCcl19-cre+;ROSA26eYFP mice. Allo-BMT reduced LN cellularity due to loss of 
radiosensitive hematopoietic cells, while absolute numbers of ROSA26-eYFP+ cells were 
preserved (Fig. 3.11A). Flow cytometric analysis and immunofluorescence microscopy revealed 
markedly increased relative frequencies of ROSA26-eYFP+ stromal cells in LN and spleen after 
allo-BMT (Fig. 3.11A-B, Fig. 3.12A), concomitant with depletion of radiosensitive lymphocytes 
and thickening of the subcapsular macrophage layer (Fig. 3.11C, Fig. 3.12B). ROSA26-eYFP+ 
fibroblastic cells from allo-BMT mice were located within both the T zone and B follicles, as 
delineated by the stromal markers podoplanin and CD35, respectively. T zone Ccl19+ 
fibroblastic cells strongly upregulated podoplanin and CD157/BP3 expression, while stromal 
cells in B follicles upregulated CD35, CD157/BP3, and MAdCAM-1 (Fig. 3.11D, Fig. 3.12C). 
Thus, allo-BMT rapidly altered the spatial organization of lymphoid organ-resident cells, 
exposing donor T cells to a dense network of highly activated stromal cells.  
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Figure 3.7. Impact of stromal cell-specific inactivation of Dll1/4 Notch ligand genes on 
proinflammatory cytokine production by CD8+ donor-derived T cells 
Detection of intracellular cytokines in donor CD8+ T cells after anti-CD3/anti-CD28 restimulation (day 6 
post-transplantation, flow cytometry) (n = 5 mice/group). Control TgCcl19-cre– recipient mice treated with 
isotype control antibodies were compared to TgCcl19-cre– mice receiving anti-Dll1/4 antibodies vs. TgCcl19-
cre+;Dll1Δ/Δ;Dll4Δ/Δ mice treated with isotype control or anti-Dll1/4 antibodies. 
 
 
Defined fibroblastic niches deliver Notch ligands to donor alloreactive T cells 
We next investigated the distribution of Notch ligands in SLOs after allo-BMT, focusing on 
Dll4 since it is the dominant Notch ligand driving GVHD [72]. We examined cell-surface Dll4 
within five distinct populations of CD45– LN stromal cells, as defined by expression of CD31, 
podoplanin, CD157/BP3 and CD21/35 (Fig. 3.13A). Comparison of control TgCcl19-cre– and 
TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice identified cellular subsets expressing functionally relevant Notch 
ligands after allo-BMT. Interestingly, Dll4 expression was not uniformly distributed among all 
Ccl19+ stromal cells, but observed in a fraction of podoplanin+CD31– FRCs marked by high 
levels of CD157/BP3 and in podoplanin+CD31–CD21/35hi cells (consistent with follicular 
dendritic cells). LECs expressed only slightly decreased Dll4 in TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice, 
in keeping with low Ccl19-Cre activity in LECs (Fig. 3.5A). Ccl19-Cre+ podoplanin+CD31– 
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Figure 3.8. Ccl19-Cre expression by itself has no impact on T cell alloreactivity after 
allogeneic bone marrow transplantation 
10x106 TCD BM + 20x106 allogeneic BALB/c splenocytes were transplanted into lethally irradiated (12 
Gy) B6 control TgCcl19-cre–, TgCcl19-cre+;Dll1+/+;Dll4+/+ or TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice. Some TgCcl19-cre– 
mice received i.p injections of isotype control or anti-Dll1/4 on days 0, 3. Detection of intracellular 
cytokines in donor CD4+ T cells and CD8+ T cells after anti-CD3/anti-CD28 stimulation at day 6 post-
transplantation (flow cytometry) (n = 5 mice/group). *P<0.05, **P<0.01. Data are representative of 2 
experiments, with error bars representing SD. 
 
CD157low FRCs had no detectable Dll4, while BECs expressed Dll4 both in control and TgCcl19- 
cre+;Dll1Δ/Δ;Dll4Δ/Δ mice (Fig. 3.13A). Immunofluorescence microscopy of spleens from TgCcl19-
cre+;Dll1+/+;Dll4+/+;ROSA26eYFP and TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ;ROSA26eYFP allo-BMT mice also 
demonstrated that only a subset of Ccl19-Cre lineage-traced eYFP+ cells expressed high levels of 
Dll4 protein. Loss of Dll4 expression was observed in both ROSA26-eYFP+CD35+ (Fig. 3.13C) 
and ROSA26-eYFP+CD157+ cells (Fig. 3.13D) in TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ;ROSA26eYFP mice. 
To assess if alloantigen-specific T cells first localize in SLOs next to Dll4-expressing stromal 
cells, we tracked alloantigen-specific CD4+ T cells during their early window of Notch 
sensitivity. We detected proliferating donor T cells close to both Dll4-expressing CD157+ and 
CD35+ fibroblasts (Fig. 3.13E-F). Altogether, our data suggest that defined fibroblastic subsets  
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Figure 3.9. Ccl19-Cre-mediated Dll1 and Dll4 inactivation preserves lymphocyte numbers 
and distribution in SLOs at steady state. 
A. Absolute numbers of CD4+ T cells, CD8+ T cells and B cells in spleen and LNs of B6 control TgCcl19-
cre– or TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice at steady state (n = 5 mice/group). B-C. CD62L and CD44 
expression in CD4+ T cells (B) and CD8+ cells (C) from spleen and LNs of TgCcl19-cre– or TgCcl19-
cre+;Dll1Δ/Δ;Dll4Δ/Δ mice at steady state. D. Abundance of Il7 transcripts (qRT-PCR) in sort-purified 
podoplanin+CD31– FRCs from TgCcl19-cre– or TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice (n = 5 mice/group). Data are 
representative of at least 3 experiments, with error bars representing SD. 
 
form specialized niches that provide Dll4 Notch ligands to incoming T cells and promote their 
pathogenic properties at the onset of GVHD. 
Discussion 
Preclinical models identified donor and host hematopoietic APCs as critical cellular partners 
of donor T cells at the onset of GVHD [128, 143]. Early interactions between donor T cells and  
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Figure 3.10. Ccl19-Cre-mediated Dll1 and Dll4 inactivation does not impair T cell 
recruitment and proliferation in SLOs post-irradiation. 
A-D. Absolute numbers (A), proliferation (CFSE dilution), (B) and expression of activation markers (C-
D) by donor-derived CD4+ and CD8+ T cells after transplantation into lethally irradiated (12 Gy) control 
TgCcl19-cre– or TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ B6 recipients. Donor cells were isolated at day 2.5 post-
transplantation (n = 5 mice/group). E. Proliferation (CFSE dilution) of donor CD4+ and CD8+ T cells at 
day 6. *P<0.05, **P<0.01. Data are representative of at least 3 experiments, with error bars showing SD. 
 
APCs, in concert with inflammatory signals from the microenvironment, are thought to provide 
essential instructive signals to induce T cell alloreactivity. Our findings revise this prevailing 
model of GVHD pathogenesis, as they identify LN and spleen-resident Ccl19+ FRCs as key 
initiators of alloimmune T cell pathogenicity through induction of Notch signals in donor-
derived T cells. Contrary to past assumptions, donor and host hematopoietic APCs were not 
responsible for delivery of Notch signals to donor T cells, as genetic inactivation of Delta-like 
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Notch ligands within donor and host hematopoietic APCs failed to ameliorate GVHD. In 
contrast, selective inactivation of Notch ligands within Ccl19+ FRCs resulted in long-term 
protection from GVHD. Thus, specialized fibroblastic niches are uniquely important in the 
context of alloimmunity.  
Immunofluorescence microscopy and flow cytometric analysis of SLOs post-
allotransplantation demonstrated that Delta-like Notch ligand expression was not uniformly 
distributed throughout all FRCs. Instead, we observed focal niches of Notch ligand expression 
within Ccl19-Cre+ cells marked by the stromal surface markers CD157 and CD21/35. 
Concomitant expression of chemokines and Delta-like Notch ligands in resident non-
hematopoietic cells within defined SLO niches bears similarities to the co-regulated expression 
of chemokines and Dll4 ligands in cortical thymic epithelial cells. In the thymus, Foxn1 controls 
expression of CCL21/25 and Dll4, which is critical to attract lymphoid progenitors and induce T 
lineage development [133]. We speculate that SLOs rely on a similar organizational module to 
attract immune cells to defined niches with specialized immunological functions in which they 
are exposed to Notch ligands and other regulatory signals. This is consistent with the role of 
FRCs as a source of Notch ligands for marginal zone B cells, Esamhi DCs and T follicular helper 
cells [123]. During alloimmune responses, direct interaction of T cells with these defined stromal 
niches may deliver important molecular cues in a temporally and spatially controlled fashion. An 
in-depth characterization of the cellular and humoral signals delivered within these defined 
niches should provide additional critical insight into the molecular pathogenesis of GVHD. 
Furthermore, upstream signals and transcription factors controlling the expression of Delta-like 
Notch ligands and chemokines in FRC niches remain to be discovered. 
 
  49 
 
Figure 3.11. Irradiation increases the relative density and activation of Ccl19+ stromal cells 
A. Total cellularity, absolute numbers of CD45+ cells, and absolute numbers and frequencies of eYFP+ 
cells in LNs of unirradiated or lethally irradiated (12 Gy) TgCcl19-cre+;ROSA26eYFP reporter mice receiving 
allogeneic BALB/c splenocytes (n = 6 mice/group). B. Immunofluorescence microscopy of LN 
cryosections from TgCcl19-cre+;ROSA26eYFP mice stained for GFP. Cryosections were prepared from 
unirradiated or lethally irradiated (12 Gy) mice receiving no T cells, syngeneic B6 CD4+ T cells, or 
allogeneic BALB/c CD4+ T cells. C-D. Immunofluorescence microscopy of LN cryosections from TgCcl19-
cre+;ROSA26eYFP mice stained for B220 and CD3 (C, top panel), GFP, CD11b, and CD169 (C, bottom 
panel), GFP and podoplanin/gp38 (D, top panel) or GFP and CD35 (D, bottom panel). Cryosections 
were prepared from unirradiated or lethally irradiated (12 Gy) mice receiving allogeneic BALB/c CD4+ T 
cells at day 1.5 post-transplantation. Data are representative of 2 experiments. 
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Figure 3.12. Impact of allogeneic bone marrow transplantation on spleen architecture. 
A-C. Immunofluorescence microscopy of spleen cryosections from TgCcl19-cre+;ROSA26eYFP reporter mice 
stained for GFP only (A), B220 and CD3 (B, top panel), GFP, CD11b, and CD169 (B, bottom panel), 
GFP and podoplanin/gp38 (C, first panel), GFP and CD35 (C, second panel), GFP and MAdCAM1 (C, 
third panel), or GFP and CD157/BP3 (C, fourth panel). Cryosections were prepared from unirradiated 
or lethally irradiated (12 Gy) mice receiving allogeneic BALB/c CD4+ T cells at day 1.5 post-
transplantation. The high intensity of CD35 staining in the absence of irradiation is due to expression of 
CD21/35 by B cells. After irradiation and depletion of radiation-sensitive B cells, CD35 staining 
highlighted stromal cells in the B cell follicles consistent with follicular dendritic cells. Data are 
representative of 2 experiments. 
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Figure 3.13. Fibroblastic niches express Delta-like1/4 Notch ligands and localize next to 
alloreactive T cells. 
A. Dll4 expression in LN-resident non-hematopoietic cells from control TgCcl19-cre– and TgCcl19-
cre+;Dll1Δ/Δ;Dll4Δ/Δ mice transplanted with allogeneic BALB/c splenocytes. B-C. Immunofluorescence 
microscopy of spleen cryosections from TgCcl19 cre+;Dll1+/+;Dll4+/+;ROSA26eYFP or TgCcl19-
cre+;Dll1Δ/Δ;Dll4Δ/Δ;ROSA26eYFP mice stained for GFP, CD35 and Dll4 (B) or GFP, CD157, and Dll4 (C). 
D-F. Immunofluorescence microscopy of spleen cryosections from lethally irradiated (8.5 Gy) BALB/c 
mice transplanted with CMTMR-labeled alloantigen-specific CD4+ 4C T cell receptor transgenic cells 
and pulsed with EdU 12 hours prior to organ collection. Cryosections were stained with Alexa Fluor 488 
picolyl azide for EdU, along with anti-Dll4 (D), anti-CD157 (E) or anti-CD35 (F). Organs were collected 
at day 1.5 post-transplantation. **P<0.01, ***P<0.001. Data are representative of at least 2 experiments, 
with error bars indicating SD. 
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FRCs support steady-state immune homeostasis through the secretion of IL-7 and CCL19 
[106]. In vitro, FRCs enhance naïve CD4+ or CD8+ T cell survival and viability in an IL-
7/CCL19-dependent manner, while Ccl19 loss in vivo results in decreased total numbers of CD4+ 
and CD8+ T cells. Importantly, genetic Dll1/4 inactivation of Notch ligands with Ccl19-Cre did 
not negatively impact the ability of FRCs to maintain naïve T cell homeostasis, as the total 
number of immune cells within LN and spleen and the distribution of naïve/memory cells at 
steady-state were unaffected. Consistent with this notion, Il7 transcripts were unaltered in sort-
purified FRCs from TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice, showing that Dll1/4 loss did not globally 
disrupt FRC function. 
FRCs can regulate immunity through multiple mechanisms. FRCs form a scaffold to which 
DCs can adhere and present antigens to naïve T cells, thus using the FRC network as a ‘road 
system’ for their migration [92]. This random migration is enhanced by the chemokines CCL19 
and CCL21, constitutively expressed by FRCs. Physical removal of FRCs after SLO 
development prevents the efficient activation and proliferation of antigen-specific T cells [139]. 
In contrast, in our studies, genetic Dll1/4 inactivation with Ccl19-Cre preserved T cell homing, 
as equivalent numbers of donor CD4+ and CD8+ T cells were isolated in SLOs. Furthermore, 
donor T cells upregulated the early activation markers CD69 and CD44 upon transfer into 
TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice, suggesting their preserved ability to encounter and respond 
initially to alloantigens. Finally, donor T cells demonstrated no obvious impairment in their 
ability to proliferate in response to antigen. Thus, our observations differ from the broader 
dysfunction of SLOs observed upon physical elimination of Ccl19+ FRCs [139]. Instead, our 
targeted genetic approach suggests that FRC subsets regulate specific aspects of immune cell 
biology through dedicated signaling pathways (e.g. Notch), consistent with the delivery of 
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unique activation codes to immune cell subsets. Moreover, the post-transplant environment may 
enhance the delivery of Notch signals to incoming T cells though FRC activation after irradiation 
and loss of radiation-sensitive host lymphocytes.  
Our in vivo results contrast with past work identifying a role for stromal cells as negative 
regulators of immune responses [113-115], as the dominant role of these cells after allo-BMT in 
our study was to promote rather than to restrain alloimmune reactivity. In previous studies, the 
addition of ex vivo isolated FRCs to T cell/DC cocultures suppressed T cell proliferation in a 
dose-dependent fashion. Suppression was mediated by IFNγ-dependent upregulation of NOS2 
and COX1/2-dependent metabolites within FRCs. While nos2 inactivation resulted in enhanced 
T cell proliferation in vivo, the lack of specificity of the genetic targeting strategy made it 
difficult to assess whether FRCs were in fact responsible for enforcing this suppressive 
mechanism. Furthermore, the expression of Notch ligands on FRCs was not examined in the in 
vivo or in vitro studies. In our in vivo studies, irradiation of allotransplant recipients upregulated 
expression of several surface markers on stromal cells, changed their morphology, and resulted 
in profound remodeling of SLO microanatomy within the first few days after transplantation. 
Thus, it is possible that the highly inflammatory environment that ensues post-irradiation, in 
combination with the differences in the nature and availability of antigen, can account for the 
extreme proinflammatory functions of FRCs after allo-BMT. It is also possible that alloreactive 
T cells gain unique access to fibroblastic niches from which T cells are typically excluded, such 
as follicular dendritic cells or follicular FRCs residing in the B cell zone. Alternatively, our 
observations may reveal a previously unrecognized proinflammatory function of stromal cells 
mediated by Notch signaling that also operates in other contexts. 
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In terms of temporal requirement for Notch signaling, systemic delivery of Dll1/4 blocking 
antibodies at the time of transplantation had profound effects on T cell cytokine production, Treg 
expansion, and overall T cell alloreactivity, but inhibition delayed by only two days failed to 
efficiently block GVHD. This narrow window of therapeutic sensitivity is significant in terms of 
translational applications. Indeed, short-term Dll1/4 inhibition during this critical time emerges 
as an attractive therapeutic strategy to prevent GVHD without exposing recipients to the risks of 
long-term Dll1/4 blockade. Mechanistically, this narrow window of therapeutic sensitivity might 
reflect the temporal delivery of a physical pulse of Notch signaling in defined microanatomical 
niches after allo-BMT. This physical pulse may result from transient exposure to cellular sources 
of Notch ligands that are typically inaccessible to alloreactive T cells, or from prolonged initial 
contacts with FRC subsets that upregulate Dll1/4. Alternatively, our findings could reflect a 
unique window of T cell sensitivity to Notch signaling during early stages of priming and 
activation. 
Altogether, our study reveals for the first time the existence of specialized subsets of host 
nonhematopoietic fibroblastic cells delivering Notch signals to donor T cells at early stages after 
allo-BMT to program their pathogenicity. Donor and host hematopoietic APCs were dispensable 
sources of Notch ligands, thus challenging the widely accepted hypothesis that motile APCs 
simultaneously provide both antigen and Notch ligands to prime T cells. These findings illustrate 
the importance of exploring Notch signaling in vivo using loss-of-function approaches, as 
relevant sources of Notch ligands may be missing from established in vitro experimental 
systems. Our work also highlights the utility of precisely targeting immunomodulatory pathways 
in stromal cells, as we uncovered a previously unrecognized pathogenic role for FRCs 
independent of their functions in structural integrity and immune homeostasis. In GVHD, 
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allograft rejection and other immune disorders, our findings pave the way towards selective 
inhibition of niche-derived signals that drive deleterious immune responses, without interfering 
with other essential immunological functions of the lymphoid environment. 
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Chapter 4 
 
Molecular effects of Notch signaling on alloreactive CD4+ T conventional cells 
during in vivo priming 
Abstract 
Graft-versus-host disease (GVHD) is the most serious complication of allogeneic bone marrow 
transplantation (allo-BMT).  We recently identified that Notch signaling during the first 48 hours 
after allo-BMT drives proinflammatory cytokine production in conventional CD4+ T cells 
(Tconv) and inhibits the expansion of CD4+ FoxP3+ regulatory T cells (Tregs).  Inhibition of 
Notch signals during this 48-hour window results in long-term clinical protection from GVHD.  
However, it is unclear whether the clinical consequences of Notch inhibition are dependent on its 
effects on Tconv, Tregs, or both.  Furthermore, limited tools are available for examining the 
molecular events that occur in alloantigen-specific T cells during this early window of Notch 
activity.  In this study, we identified a Tconv-intrinsic role for Notch signaling in mediating 
acute GVHD.  We established a new model of acute GVHD with a clonal population of 
alloantigen-specific CD4+ Tconv cells that enabled us to examine the molecular impact of Notch 
signaling on alloreactive T cell priming.  During T cell priming, Notch-deprived T cells 
exhibited no defects in the early steps of activation, preserved their ability to produce IL-2, 
proliferated normally, and induced the transcription of tbx21, rorc, and gata3.  In contrast, Notch 
inhibition prevented the acquisition of IFNγ and IL-17 production, diminished mTORC1 and 
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ERK1/2 activity, and impaired the transcription of a subset of Myc-dependent target genes.  
Thus, unlike standard global immunosuppression, Notch inhibition in alloantigen-specific Tconv 
CD4+ cells resulted in the dissociation of proliferation from effector function acquisition.  These 
findings provide a mechanistic explanation for how Notch inhibition modulates T cell 
alloreactivity differently than standard global immunosuppressants. 
Introduction 
Notch signaling is an evolutionarily conserved signaling pathway that has important effects 
during development and homeostasis of the immune system, and during active immune 
responses [144].  Physical interactions between Notch1-4 receptors and Delta-like1/3/4 
(Dll1/3/4) or Jagged1/2 Notch ligands trigger sequential ADAM10 and γ-secretase complex-
mediated proteolytic cleavage of Notch, releasing the intracellular domain to regulate 
transcription of target genes.  Notch has emerged as an essential regulator of T cell alloreactivity 
in mouse models of graft-versus-host disease and allograft rejection [71-73, 75-78].  We 
previously demonstrated that genetic blockade of Notch signaling within donor CD4+ and CD8+ 
T cells resulted in long-term protection from GVHD mortality [71, 73].  Pharmacologic 
inhibition of Dll1/4 Notch ligands with systemic neutralizing antibodies also achieved the same 
effect [72].  Mechanistically, Notch-deprived CD4+ and CD8+ T cells at day 5 post-
transplantation exhibited profoundly defective IFNγ and IL-2 production, blunted Ras/MAPK 
signaling, and increased transcript levels of negative regulators of T cell signaling [73].  
Importantly, these effects appeared to occur independently of the master transcription factors 
(TFs) T-bet and Eomesodermin (Eomes), as Notch inhibition preserved the expression of both.  
However, as we recently identified that nearly all essential Notch signals are delivered to 
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alloreactive T cells during the first 2 days post-transplantation (Chapter 3), it is unclear whether 
these observed defects are direct consequences of Notch inhibition, or whether they are reflective 
of secondary effects and/or compensatory networks.  Therefore, we sought to assess the impact 
of Notch signaling on molecular events that occur during alloreactive T cell priming, which 
coincides with when essential Notch signals are delivered. 
Studies in T cell acute lymphoblastic leukemia (T-ALL) cell lines, >50% of which harbor 
Notch gain-of-function mutations, have provided key insights into the potential molecular 
mechanisms that operate downstream of Notch [24].  Chromatin immunoprecipitation (ChIP) 
and γ-secretase inhibitor (GSI) washout studies revealed a comprehensive list of direct 
transcriptional targets of Notch [25, 26].  Two functionally important direct targets, myc and 
hes1, have been extensively studied.  Overexpression of Myc is sufficient to rescue some GSI-
treated T-ALL cell lines from undergoing G0/G1 cell cycle arrest [145, 146].  Notch directly 
regulates myc expression by forming dimerized transcriptional complexes on a long-range 
enhancer that is >1 Mb 3’ distal to the gene body [147, 148].  The basic-helix-loop-helix gene 
Hes1 encodes a transcriptional repressor that is important for neuronal stem cell maintenance, T 
cell development, and T-ALL maintenance and survival [149-151].  During T cell development 
and in T-ALL, Hes1 was shown to directly represses pten expression by binding to its promoter 
region, in addition to other putative functions.  Hes1-mediated inhibition of pten transcription 
increases AKT activity, resulting in increases in cell survival and growth [152, 153].  Therefore, 
the Notch1-Hes1-PTEN axis can promote AKT signaling.  
While RNA-Seq and ChIP-Seq studies have not been performed in Notch-dependent mature 
CD4+ T cell responses, several findings have indicated that it behaves in a highly context-
dependent manner [67, 70, 73, 86].  Recently, two major studies proposed two different (but not 
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mutually exclusive) models for how Notch operates.  In the first model, Notch acts as an 
unbiased amplifier of T helper differentiation by simultaneously binding to multiple T helper 
lineage fate transcription factor [55] and cytokine loci [69].  Prior work potentially supported this 
model, as they identified direct binding of Notch to foxp3, gata3, rorc, tbx21, il4, ifng, and il9 
[50, 69, 82, 154, 155].  In the second model, Notch promotes antigen sensitivity in a CD28-
dependent fashion [70].  Concomitant exposure of antigen-specific T cells to Dll4 signals 
enhanced T cell proliferation, upregulation of activation markers, and IL-2 production.  As both 
studies primarily utilized in vitro approaches with artificial levels of Notch ligand and antigen, it 
is unclear whether these mechanisms would operate in vivo in the context of T cell alloimmunity. 
A recent study demonstrated that genetic inactivation of Notch signaling specifically in 
FoxP3+ regulatory T cells (Tregs) was sufficient to confer long-term protection from acute 
GVHD [78].  However, the importance of Notch within FoxP3- T conventional cells (Tconv) was 
not assessed.  Given that genetic inhibition of Notch signaling in mature CD4+ and CD8+ T cells 
exerts effects on both Tconv and Tregs, we first assessed the relative importance of Tconv and 
Tregs in mediating the protective effects of Notch inhibition in a polyclonal model of MHC-
mismatched GVHD.  Next, we established a novel model of GVHD with a clonal population of 
donor alloantigen-specific CD4+ T cells.  This model allowed us to dissect the molecular effects 
of Notch within alloantigen-specific cells during in vivo T cell priming.  We assessed the impact 
of Dll1/4 inhibition on early T cell activation, signal transduction, and acquisition of cytokine 
production.  Furthermore, we performed RNA-Seq analysis on Notch-deprived alloreactive T 
cells during priming.  We identified an important role for Notch signaling within Tconv cells.  
Notch inhibition within Tconv cells preserved early T cell activation, early T cell expansion, IL-
2 production, and the transcriptional induction of tbx21, gata3, and rorc.  In contrast, Notch-
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deprived T cells failed to induce the transcription of several proinflammatory cytokines, 
displayed reduced mTORC1 and MAPK activity, and exhibited features of diminished Myc 
function despite preserved myc transcription.  Collectively, these data suggest that Notch 
inhibition results in the dissociation of proliferation from effector function acquisition. 
 
Results 
Notch signaling in CD4+ T conventional cells is an important mediator of acute GVHD 
We previously reported an essential role for Notch signaling in mature CD4+ T cells during 
acute GVHD [71-73].  Conditional expression of the pan-Notch inhibitor dominant negative 
Mastermind-like (DNMAML) in mature T cells inhibits proinflammatory cytokine production by 
FoxP3- CD4+ conventional T cells (Tconv) and expands pre-existing FoxP3+ natural regulatory T 
cells (nTregs).  Whether long-term protection from GVHD mortality is dependent on the effects 
of Notch inhibition on Tconv, nTregs, or both Tconv and nTregs is unclear.  To address this 
question, we used B6 FoxP3-IRES-RFP [156] or B6 FoxP3-IRES-RFP;Tgcd4-cre;ROSADNMAML/+ 
(FIR-DNMAML) mice as a source of donor CD4+ Tconv and nTregs.  WT RFP- Tconv, WT 
RFP+ nTreg, DNMAML+/RFP- Tconv, and DNMAML+/RFP+ nTreg were sort-purified and 
mixed together to generate four different Tconv /nTreg donor inoculums: 1) WT Tconv + WT 
nTreg; 2) WT Tconv + DNMAML nTreg; 3) DNMAML Tconv + WT nTreg; 4) DNMAML 
Tconv + DNMAML nTreg (Fig. 4.1A).  We took this approach because we had previously 
observed that depletion of nTregs from DNMAML donors prior to transplantation completely 
prevented the expansion of Tregs [73].  Thus, Notch inhibition expands pre-existing nTregs, 
rather than converting Tconv to induced Tregs [73].  Each inoculum was adoptively transferred 
with T cell-depleted (TCD) bone marrow (BM) into lethally irradiated MHC-mismatched 
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BALB/c recipients. As expected, a majority of recipients of WT Tconv + WT nTreg (56%) 
succumbed to GVHD mortality by day 45 post-transplantation.  Similarly, recipients of WT 
Tconv + DNMAML nTreg (80%) also succumbed to GVHD mortality (Figure 4.1B).  There 
was no statistically significant difference in survival rate between WT Tconv + WT nTreg and 
WT Tconv + DNMAML nTreg recipient groups, suggesting that DNMAML nTreg by 
themselves were not sufficient to confer long-term protection from GVHD mortality.  In 
contrast, 70% of recipients of DNMAML Tconv + WT nTreg, and 89% of recipients of 
DNMAML Tconv + DNMAML nTreg survived by day 45 post-transplantation (Fig. 4.1B).  
There was no statistically significant difference in survival rate between DNMAML Tconv + 
WT nTreg and DNMAML Tconv + DNMAML nTreg recipient groups, suggesting that Notch 
inhibition in Tconv was sufficient to confer long-term protection from GVHD mortality.  Thus, 
in contrast to the recent finding that genetic inactivation of Notch within Tregs is sufficient to 
protect from GVHD, these data highlight an essential role for Notch in CD4+ Tconv cells in 
mediating acute GVHD. 
Establishment of a MHC-mismatched GVHD mouse model with a clonal population of donor 
CD4+ T cells 
Sort purification and mixing of Tconv with Tregs from WT or DNMAML mice allowed us to 
identify a functionally important role for Tconv-intrinsic Notch signaling during GVHD.  As we 
had previously determined that essential Notch signals are delivered during the first 48 hours 
after allo-BMT (Chapter 3), we next sought to assess the impact of Notch on alloantigen-
specific Tconv cells during this early window of activity.  However, this was not achievable in 
the B6 anti-BALB/c model of GVHD, as neither cell proliferation nor the early activation  
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Figure 4.1. Conventional T cell-intrinsic Notch signaling is important for mediating GVHD 
after MHC-mismatched allogeneic bone marrow transplantation 
A. Experimental design for assessing the importance of conventional T cells (Tconv) and regulatory T 
cells (Tregs) in mediating the protective effects of Notch inhibition after allogeneic bone marrow 
transplantation.  Tconv and Tregs were sort purified from CD4+-enriched cells from B6 FoxP3-IRES-RFP 
[156] or B6 FoxP3-IRES-RFP;Tgcd4-cre;ROSADNMAML/+ (FIR-DNMAML) mice, and mixed at a ratio of 8:1 
Tconv:Tregs (500,000:62,500) to generate four different donor cell groups.  B. Survival and weight 
changes of lethally irradiated (8 Gy) BALB/c mice transplanted with the four experimental groups 
described in A (n = 8-10 per experimental group).  *P<0.05.  Data are representative of 2 experiments. 
 
markers CD69 and CD44 were sufficient to distinguish alloantigen-specific T cells from 
bystander cells (data not shown).  Therefore, we established a new mouse model of MHC-
mismatched GVHD that utilized 4C x Rag1-/- TCR transgenic mice as a source of donor CD4+ T 
cells.  4C cells are a clonal population of Vβ13+ CD4+ T cells that react against I-Ad MHC class 
II through direct antigen recognition [157].  Utilizing 4C x Rag1-/- donor mice conferred two 
major benefits that were unattainable with our first experimental approach. First, it enabled us to 
isolate and study a pure, clonal population of alloreactive CD4+ T cells that were not 
contaminated with confounding bystander cells that were not alloantigen-specific.  Second, it 
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allowed us to assess the importance of Notch in Tconv in the complete absence of Tregs, as 
Rag1-/- mice lack Tregs.  
As 4C cells have only been utilized to investigate MHC-mismatched allograft rejection 
[157], we first investigated whether 4C donor cells could induce GVHD mortality.  To this end, 
we transplanted >105, 2x104, or 2x103 donor 4C cells with TCD BM into lethally irradiated 
BALB/c mice and tracked GVHD survival.  We included a group of polyclonal B6 donor cells + 
TCD BM recipients to compare the kinetics of GVHD induction.  4C cells were potent inducers 
of GVHD mortality in a dose-dependent fashion (Fig. 4.2A).  Transplantation of  >105 4C cells 
resulted in 100% GVHD mortality within 4-5 days, while transplantation of 2x104 4C cells 
resulted in 100% GVHD mortality within 9-14 days. 2x103 4C cells resulted in 50% GVHD 
mortality, with all lethality happening within 9-14 days.  The remaining recipients of 2x103 4C 
cells survived long-term, potentially suggesting that 4C cells eventually became exhausted and 
were unable to cause long-term disease.  The rapid kinetics of lethality that was observed with 
higher 4C donor numbers was reminiscent of hyperacute GVHD.  Consistent with a model of 
hyperacute GVHD, 4C cells caused GVHD lethality much more rapidly than polyclonal B6 
donor cells, which induced lethality ~60 days post-transplantation.    
Consistent with in vivo activation, 4C cells from MHC-mismatched BALB/c recipients 
displayed greater size and granularity when compared to 4C cells from autologous B6-SJL 
recipients (Fig. 4.2B). 
Delta-like1/4-mediated Notch signals within donor CD4+ T cells drive GVHD mortality 
We previously reported that in polyclonal models of MHC-mismatched GVHD, CD4+ T cells 
receive their Notch signals through Dll1/4 ligands [72].  To assess whether 4C CD4+ cells also  
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Figure 4.2. CD4+ 4C TCR transgenic donors can induce lethal GVHD after MHC-
mismatched allogeneic bone marrow transplantation 
A. Survival of lethally irradiated BALB/c mice transplanted with 5x106 TCD BM only, 5x106 TCD BM + 
5x106 polyclonal B6 splenocytes, 5x106 TCD BM + >105 4C Rag1-/- splenocytes, 5x106 TCD BM + 4C 
Rag1-/- splenocytes, or 5x106 TCD BM + 2x103 4C Rag1-/- splenocytes.  B. Forward scatter (FSC-A) and 
side scatter (SSC-A) of 4C cells isolated from lethally irradiated allogeneic BALB/c or syngeneic B6-SJL 
recipients at day 1.5 post-transplantation.  In experiments described in (A-B), BALB/c mice were 
irradiated at 8 Gy, while B6-SJL mice were irradiated at 12 Gy.  Data are representative of at least 3 
experiments. 
 
received their Notch signals through Dll1/4 ligands in vivo, we transferred 2x104 4C cells and 
TCD BM into lethally irradiated BALB/c mice with or without systemic neutralizing antibodies 
against Dll1/4.  While 100% of isotype control recipients succumbed to GVHD within 10 days, 
50% of aDll1/4-treated recipients survived long-term (Fig. 4.3A). The same degree of protection 
(50%) was achieved with 2x103 donor 4C cells, as 50% of isotype control recipients succumbed 
to GVHD, while 25% of aDll1/4-treated recipients survived long-term (data not shown). 
Consistent with our results from polyclonal donor models of GVHD, systemic aDll1/4 treatment 
profoundly inhibited IFNγ, IL-2, IL-17, and TNFα cytokine production by ex vivo restimulated 
4C cells at day 5 post-transplantation (Fig. 4.3B). Thus, Notch signals drive 4C alloreactivity in 
vivo in a Dll1/4-dependent manner.   
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Figure 4.3. Systemic Dll1/4 inhibition protects from CD4+ 4C transgenic donor-induced 
GVHD mortality after MHC-mismatched bone marrow transplantation 
A. Survival of lethally irradiated (8 Gy) BALB/c mice transplanted with 5x106 TCD BM only or 5x106 
TCD BM + 2x103 4C Rag1-/- splenocytes.  Isotype control or anti-Dll1/4 neutralizing antibodies were 
injected i.p on day 0 only (n = 10/group).  B. Intracellular cytokine staining in donor 4C cells after anti-
CD3/CD28 restimulation at day 5 post-transplantation (n = 5 mice/group).   
 
Notch inhibition preserves early activation marker expression, but impairs S6 and ERK1/2 
phosphorylation 
CD4+ T cells undergo T cell priming in three distinct stages within a period of 48 hours 
[158].  First, CD4+ T cells search and encounter antigen.  Upon antigen recognition through the 
TCR, CD4+ T cells upregulate early activation markers, nutrient sensors, and cytokine receptors.  
During the second stage, CD4+ T cells acquire the ability to produce cytokines by integrating 
signals that are received through the TCR and TCR-induced surface markers/receptors [159-
161].  Finally, during the third stage, CD4+ T cells proliferate.  Given the profound effects of 
Dll1/4 inhibition on the production of multiple proinflammatory cytokines (Fig. 4.3B), we 
systematically evaluated whether Notch inhibition impacted molecular events that occur during 
T cell priming.   
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The Nur77-GFP allele has been utilized as a quantitative readout of overall TCR signal 
strength, both during T cell development and during peripheral T cell responses [162, 163].  
Unlike the early activation marker CD69, Nur77-GFP has been reported to be insensitive to 
inflammatory stimuli such as TLR agonists and type I interferons, thus possibly making it a 
reliable readout of TCR strength even during highly inflammatory settings such as allo-BMT.  
However, this has not been formally tested.  To assess whether the Nur77-GFP allele could be 
used to quantify I-Ad alloantigen-dependent signals even after irradiation, we generated 4C x 
Nur77-GFP x Rag1-/- mice.  We compared GFP levels in 4C donor cells that were transplanted 
into lethally irradiated I-Ad+ BALB/c recipients or lethally irradiated I-Ad- autologous B6-SJL 
recipients.  As kinetic analysis of cell division rate with efluor450 dye labeling of donor 4C cells 
revealed that no cell divisions occurred until after 24 hours post-transplantation (Fig. 4.4A), we 
examined GFP levels at day 1 post-transplantation.  Indeed, transfer of 4C x Nur77-GFP x Rag1-
/- donor cells into MHC-mismatched BALB/c recipients resulted in higher levels of GFP 
compared to 4C donor cells that were transferred into autologous B6-SJL recipients (Fig. 4.4A), 
suggesting that the Nur77-GFP could be utilized to quantify TCR signal strength during allo-
BMT.  Next, we assessed the impact of Dll1/4 inhibition on Nur77-GFP levels, cell size, and the 
expression of the early activation markers CD69, CD44, and CD25. Dll1/4 inhibition had no 
effect on Nur77-GFP levels at day 1 post-transplantation (Fig. 4.4B).  We also observed no 
changes in cell size at day 1 post-transplantation or expression of the early T cell activation 
markers CD69 and CD44 at day 1.5 post-transplantation (Fig. 4.4B).  However, CD25 
expression at day 1.5 post-transplantation was reduced, consistent with previous reports that 
CD25 is a direct target of Notch signaling [35, 83, 85, 142].  
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Next, we assessed whether Dll1/4 inhibition altered signal transduction during T cell 
priming. Two major signaling pathways that are collectively activated by the TCR, costimulatory 
pathways, nutrient sensors, and cytokine receptors are the mTORC1 pathway and the Ras/MAPK 
pathway.  To assess whether Dll1/4 inhibition impacted either of these pathways, we performed 
phosphoflow cytometry for the mTORC1 target S6 and the MAPK target ERK1/2 at day 1 post-
transplantation.  To control for specificity of phosphoflow staining, we labeled Thy1.1+ 4C and 
Thy1.2+ autologous BALB/c with efluor450 cell proliferation dye, and cotransplanted both donor 
populations into lethally irradiated BALB/c recipients (Fig. 4.4C).  As expected, pS6 and 
pERK1/2 levels were higher in alloreactive 4C cells compared to autologous BALB/c cells (Fig. 
4.4C).  Dll1/4 inhibition resulted in a statistically significant decrease in both pS6(S235/S236) 
and pS6(S240/S244) levels, suggesting an impairment in mTORC1 signaling (Fig. 4.4D). Dll1/4 
inhibition also resulted in a statistically significant decrease in pERK1/2 levels, suggesting a 
defect in Ras/MAPK activity.  Collectively these data suggested that Notch inhibition impairs 
key signal transduction events during T cell priming. 
Notch inhibition preserves early IL-2 and TNFα  production, but impairs IFNγ  and IL-17 
production 
Next, we assessed the impact of Dll1/4 inhibition on proinflammatory cytokine acquisition 
during the later stages of T cell priming, at day 1.75 post-transplantation.  Similar to our 
observations at day 5 post-transplantation (Fig. 4.3B), Dll1/4 inhibition resulted in significant 
decreases in IFNγ and IL-17 production (Fig. 4.5A).  In contrast, Dll1/4 inhibition had no  
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Figure 4.4. Impact of systemic Dll1/4 inhibition on key molecular events that occur during 
T cell priming 
A. Nur77-GFP levels in 4C cells from spleen and LNs of lethally irradiated allogeneic BALB/c or 
syngeneic B6-SJL recipients at day 1 post-transplantation. B. Nur77-GFP levels, FSC-A, and activation 
marker expression in 4C donors from spleen and LNs of lethally irradiated (8 Gy) BALB/c + isotype 
control or BALB/c + aDll1/4 recipients.  Nur77-GFP and FSC-A was assessed at day 1 post-
transplantation, while activation marker expression was assessed at day 1.5 post-transplantation.  C. 
Experimental strategy for phosphoflow cytometry analysis.  pS6(S235/S236), pS6(S240/S244), and 
pERK1/2 staining in allogeneic 4C and autologous BALB/c cells from the same lethally irradiated (8 Gy) 
BALB/c recipient at day 1 post-transplantation.  D. pS6(S235/S236), pS6(S240/244), and pERK1/2 
staining in 4C cells from spleen and LNs of lethally irradiated (8 Gy) BALB/c + isotype control or 
BALB/c + aDll1/4 recipients at day 1 post-transplantation.  In all experiments described in (A-D), isotype 
control or anti-Dll1/4 neutralizing antibodies were injected i.p. on day 0 only.  Data are representative of 
at least 3 experiments. 
 
impact on IL-2 and TNFα production (Fig. 4.5A).  Consistent with the initial preservation of IL-
2 production, 4C cells from Dll1/4-inhibited BALB/c recipients did not exhibit a defect in the 
dilution of the cell tracking dye CMTMR (Fig. 4.5B).  These data suggest that during T cell 
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priming, Notch-deprived alloreactive CD4+ T cells initially acquire the ability to produce IL-2 
and TNFα, while immediately becoming defective in their ability in produce IFNγ and IL-17. 
Figure 4.5. Systemic Dll1/4 inhibition preserves the acquisition of IL-2 and TNFα  
production, but not IFNγ  and IL-17 production, during T cell priming 
A. Intracellular cytokine staining in donor 4C cells from lethally irradiated (8 Gy) BALB/c + isotype 
control or BALB/c + aDll1/4 recipients after anti-CD3/CD28 restimulation at day 1.75 post-
transplantation (n = 5/group). B. Proliferation (CMTMR dilution) by donor 4C cells from lethally 
irradiated syngeneic B6-SJL, BALB/c + isotype control, or BALB/c + aDll1/4 recipients at day 1.75 post-
transplantation.  B6-SJL recipients were irradiated at 1200 Gy, while BALB/c recipients were irradiated 
at 8 Gy.  In both panels A and B, isotype control or anti-Dll1/4 neutralizing antibodies were injected i.p. 
at day 0 only.  *P<0.05.  Data are representative of 3 experiments, with error bars showing SD. 
 
Transcriptional profiling of alloreactive T cells 
We previously reported that Notch exerts its functional effects on CD4+ and CD8+ T cell 
alloreactivity through transcriptional regulation of target genes [72, 73].  To define the effects of 
Notch on the transcriptional landscape of alloreactive CD4+ cells during T cell priming, we 
performed RNA-Seq analysis on sort-purified CD4+ 4C cells from three different experimental 
groups at day 1.5 post-transplantation: 1) 4C -> I-Ad+ BALB/c + isotype control; 2) 4C -> I-Ad+ 
BALB/c + aDll1/4; 3) 4C -> I-Ad- B6-SJL + isotype control.  Comparison of group 1 (4C -> 
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BALB/c + isotype control) to group 3 (4C -> B6-SJL + isotype control) identified genes that 
were regulated by alloantigen, while comparison of group 1 to group 2 (4C -> BALB/c + 
aDll1/4) identified genes that were regulated by Notch.  Differentially regulated transcripts were 
identified based on three criteria, which included a sufficient number of alignment reads for 
statistical analysis, a false discovery rate (q-value) of <0.05, and a relative fold change of >1.5 or 
<0.67. 
In vivo exposure of 4C cells to I-Ad alloantigen differentially regulated their expression of 
6212 genes, including the well-established TCR-dependent genes il2, ifng, and cd25 (Fig. 4.6A).  
Systemic Dll1/4 inhibition in MHC-mismatched BALB/c recipients resulted in the differential 
regulation of 945 genes, among which 526 genes were also upregulated by alloantigen.  Among 
the 945 genes that were differentially regulated by Notch, 619 genes were upregulated, while 326 
genes were downregulated.  Dll1/4 inhibition downregulated several canonical Notch target 
genes, including dtx1, hes, cd25, and trib2 (Fig. 4.6B).  Other previously reported Notch target 
genes, including myc, tbx21, gata3, rorc, foxp3, hes5, heyL, hey1, hey2, and nrarp were either 
not downregulated by Dll1/4 inhibition, or expressed below the limit of detection of RNA-Seq 
analysis (data not shown).  Finally, Notch inhibition did not regulate pten, thus making it 
unlikely that the Notch1-PTEN-Hes1 axis is functionally important in CD4+ alloreactive T cells. 
Systemic inhibition of Dll1/4-mediated Notch signals broadly impaired the transcription of 
cytokines during T cell priming, with two notable exceptions.  Ifng, il21, il17a, il17f, il10, and il-
3 transcripts were all markedly downregulated (Fig. 4.6C), while il2 and tnfa transcripts were 
unaltered (Fig. 4.6D).  These findings were consistent with our intracellular flow cytometry 
analysis at day 1.75 post-transplantation (Fig. 4.5A).  The initial preservation of il2 transcription 
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was not unique to the 4C model, as we observed the same effects in the BALB/c anti-B6 
polyclonal model (Fig. 4.6E-F). 
Several cytokine receptor transcripts, including il6st, il12rb2, il23r, il1r1, and cd25, were 
downregulated by Dll1/4 inhibition (Fig. 4.6G).  Gene Set Enrichment Analysis (GSEA) was 
consistent with this result, as we observed an enrichment in downregulated genes that are 
associated with cytokine signaling pathways (NES = -1.7), MAP kinase signaling pathways 
(NES = -1.7), and JAK/STAT signaling pathways (NES = -1.9)(Fig. 4.6H). 
GSEA also revealed that systemic Dll1/4 inhibition results in an enrichment in 
downregulated genes that are associated with Myc signaling (NES = -1.9) and an enrichment in 
upregulated genes that are associated with the Treg transcription factor FoxP3 (NES = 2.0)(Fig. 
4.6I).  Both results were surprising, as myc transcript levels were unchanged at day 1.5 (Fig. 
4.6J), while foxp3 was expressed at nearly undetectable levels in CD4+ 4C cells.   
 
Early Notch inhibition results in aberrant T cell activation 
Upon the completion of T cell priming, CD4+ T cells downregulate CD69 while maintaining 
their expression of CD44 and CD25 [102, 158].  Surprisingly, at day 3 post-transplantation, 
systemic Dll1/4 inhibition resulted in persistent surface expression of CD69 and decreased 
expression of CD25 (Fig. 4.7A).  Consistent with higher levels of CD69 expression, Nur77-GFP 
levels were also higher (Fig. 4.7B).  4C cells from aDll1/4-treated recipient mice were larger, 
exhibited higher granularity, and expressed higher levels of c-myc (Fig. 4.7C). Furthermore, 
despite expressing increased levels of the prosurvival factor Bcl2 (Fig. 4.7D), fewer 4C cells 
were present in spleens from Dll1/4-treated mice (Fig. 4.7E).  Collectively, these data suggest 
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Figure 4.6. RNA-Seq analysis of the Notch transcriptome during alloreactive T cell priming 
A. Abundance of cd25, ifng, and il2 transcripts (FPKM) in 4C cells from lethally irradiated syngeneic B6-
SJL or allogeneic BALB/c recipients at day 1.5 post-transplantation.  (B-D, G). Abundance of dtx1, hes1, 
cd25, and trib2 transcripts (B), ifng, il21, il17a, il17f, il10, and il3 transcripts (C), il2 and tnfa transcripts 
(D), il6st, il12rb2, il23r, ilr1, cd25 transcripts (G) in 4C cells from lethally irradiated BALB/c + isotype 
control or BALB/c + aDll1/4 at day 1.5 post-transplantation.  (E) Experimental strategy and flow 
cytometry plots to isolate CD4+ alloreactive T cells at day 2 post-transplantation.   Allogeneic BALB/c 
splenocytes were labeled with CFSE and injected into lethally irradiated (1200 rads) B6 mice.  Divided 
CFSElo BALB/c cells were sort-purified for gene expression analysis.  (F) Abundance of dtx1 and il2 
transcripts (qRT-PCR) in sort-purified CFSElo CD4+ T cells from lethally irradiated (1200 rads) B6 + 
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isotype control or B6 + aDll1/4 at d2 post-transplantation (n = 4 mice/group). (H,I) Gene set enrichment 
analysis (GSEA) plots for cytokine signaling, MAP kinase signaling, JAK/STAT signaling (H), Myc 
targets, and FoxP3 targets (I).  (J) Abundance of myc transcripts (qRT-PCR) in sort-purified 4C cells 
from lethally irradiated BALB/c + isotype control or BALB/c + aDll1/4 at day 1.5 post-transplantation.  
NES, normalized enrichment score.  FPKM, fragments per kilobase of transcript per million mapped 
reads.  *P<0.05. 
 
that Dll1/4 inhibition results in the aberrant acquisition of a T cell effector program that exhibits 
paradoxical features of hyperactivity. 
Discussion 
In this study, we utilized two different experimental strategies to highlight an important role 
for CD4+ Tconv-intrinsic Notch signaling in mediating GVHD pathogenicity.  First, we sort-
purified Tconv and nTregs from B6 FIR or B6 FIR-DNMAML mice to generate “synthetic” 
donor inoculums of CD4+ FoxP3- Tconv mixed with CD4+ FoxP3+ nTregs.  Notch deprivation 
within Tconv cells alone was sufficient to protect from GVHD.  In contrast, Notch deprivation 
within Tregs was not sufficient to confer protection from GVHD, as recipients of WT Tconv 
mixed with Notch-deficient Tregs were susceptible to GVHD.  Second, we developed a new 
model of GVHD with I-Ad-reactive TCR transgenic CD4+ 4C Rag1-/- donors, which completely 
lack Tregs due to the absence of I-Ad antigen within the host.  While 4C cells were potent 
inducers of GVHD mortality, they were sensitive to Notch inhibition by neutralizing antibodies 
against Dll1/4 Notch ligands.  Our findings contrast with a recently published report that genetic 
ablation of Notch signaling specifically within Tregs with foxp3-Cre was sufficient to confer 
long-protection from GVHD mortality [78].  Total splenocytes from foxp3eGFPCre;rbpjf/f or 
foxp3eGFPCre;notch1f/f donors failed to induce mortality in a B6 anti-BALB/c model of GVHD.  
However, both CD4+ and CD8+ Tconv cells from these mice exhibited a hyporesponsive  
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Figure 4.7. Systemic Dll1/4 inhibition results in aberrantly activated alloreactive T cells  
CD69 vs. CD25 expression (A), Nur77-GFP levels (B), abundance of c-myc transcripts (qRT-PCR) (C), 
intracellular Bcl2 staining (D), and absolute numbers (E) of 4C cells from spleens of lethally irradiated 
BALB/c + isotype control or BALB/c + aDll1/4 recipients at day 3 post-transplantation.  Isotype control 
or anti-Dll1/4 neutralizing antibodies were injected i.p. at day 0 only.  *P<0.05, **P<0.01.  Data are 
representative of at least 3 experiments, with error bars showing SD. 
 
phenotype on baseline, as they were defective in their ability to produce IFNγ upon 
PMA/ionomycin restimulation.  While the inability to produce IFNγ could have been the result 
of exuberant suppression of Tconv by Notch-deficient Tregs (which exhibited enhanced 
suppressive activity), the exact reason for hyporesponsiveness was not explored in detail.  Thus, 
it was possible that the recipients of foxp3eGFPCre;rbpjf/f or foxp3eGFPCre;notch1f/f splenocytes were 
protected from GVHD mortality not because of loss of Notch signaling within Tregs, but 
because the donor Tconv cells were hyporesponsive.   Assessing the ability of purified Tconv 
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cells from foxp3eGFPCre;rbpjf/f or foxp3eGFPCre;notch1f/f donor mice to induce GVHD could 
directly test this hypothesis. 
Analysis of alloreactive 4C cells provided several lines of evidence that inhibition of Notch 
signaling preserves several aspects of T cell priming.  First, Notch-deprived 4C cells displayed 
no defects in the upregulation of the activation markers CD69 and CD44.  Second, transcription 
and protein synthesis of IL-2, which receives direct inputs from the TCR through the TFs AP-1, 
and NFAT, was unimpaired by systemic Dll1/4 inhibition.  The initial preservation of IL-2 
production by CD4+ alloreactive T cells may explain why Notch inhibition in polyclonal models 
of GVHD results in the expansion of nTregs, which exquisitely depend on IL-2-mediated signals 
to proliferate and survive [164].  Third, Dll1/4 inhibition did not blunt the initial burst of 
proliferation by 4C cells.  Collectively, these findings conflict with a recent report that Notch 
enhances CD69 expression, cell size, IL-2 production, and proliferation both in vitro and in vivo 
[70]).  It is possible that depending on the strength and availability of antigen, Notch exerts 
different effects.   
Both mTORC1 activity and Ras/MAPK activity were impaired in Notch-deprived 
alloreactive T cells during priming. mTORC1 activation is regulated by several extracellular 
stimuli, including amino acids, cytokine/growth factor receptors, TCR signaling, and the B7 
family of costimulatory molecules [165, 166].  Similarly, Ras/MAPK signaling sits downstream 
of TCR signaling, cytokine/growth factor receptors, and the B7 family of costimulatory 
molecules.  Therefore, it is unclear as to whether Notch inhibition regulates some or all of the 
aforementioned pathways to modulate mTORC1 and Ras/MAPK.  While Nur77-GFP levels 
were not altered with Notch inhibition, Nur77-GFP has been reported to mainly read out TCR-
mediated Protein Kinase C (PKC) activity [163].  Thus, while diacylglycerol-dependent PKC 
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activity is most likely intact in Notch-deprived alloreactive T cells, it is entirely possible that 
Notch modulates specific arms of TCR signaling, such as DAG-dependent Ras/MAPK activation 
and/or AKT-dependent mTORC1 activation.  Alternatively, impairment of mTORC1 and 
Ras/MAPK could be due to impaired B7-mediated costimulatory signals or diminished 
cytokine/growth factor signaling.  Intact production of IL-2, which receives direct inputs from 
Ca++-dependent NFAT, costimulation-dependent NF-κB and ERK1/2-dependent AP-1 [167], 
would argue that both TCR-dependent and B7-mediated ERK1/2 activity is intact. 
Our studies represent the first RNA-Seq-based transcriptional analysis of Notch signaling in 
mature T cells.  Dll1/4 inhibition in alloreactive T cells downregulated several canonical Notch 
target genes, including dtx1, cd25, trib2, and hes1. Notably, alloreactive 4C cells expressed low 
levels of hes1, while its putative transcriptional target pten was unaffected by Notch inhibition 
(data not shown).  Thus, it is unlikely that the previously reported Notch-Hes1-PTEN axis, which 
plays an important role in both T-ALL and developing thymocytes, operates in alloreactive T 
cells [152, 153].  Consistent with our previous observations in polyclonal models of GVHD, 
Notch did not regulate the expression of key TFs that control helper CD4+ lineage fate decisions 
in mature T cells, including tbx21, rorc, gata3, and foxp3 [71, 73].  On the other hand, a wealth 
of cytokines (ifng, il21, il17a, il17f, il10, il3) and cytokine receptors (il6st, il12rb2, il23r, il1r1, 
cd25) were all downregulated by Dll1/4 inhibition.  However, it is unclear whether any of these 
regulated genes are direct targets of Notch, as the low number of 4C cells at day 1.5 post-
transplantation prevented ChIP analysis.  Thus, it is difficult to directly compare our findings to 
the recent report that Notch acts as an unbiased amplifier of T helper cell differentiation [69]. 
During T cell activation, induction of Myc is essential for the metabolic reprogramming of 
activated CD4+ and CD8+ T cells [168].  In CD8+ T cells, Myc is asymmetrically partitioned 
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upon the first division, with Mychi cells acquiring effector-like properties and Myclo cells 
acquiring memory-like properties.  Mychi cells produce higher levels of IFNγ and express high 
levels of CD25, while Myclo cells express higher levels of Bcl2 and exhibit lower levels of 
mTORC1 activity [169, 170].  Intriguingly, Dll1/4 inhibition resulted in the downregulation of 
Myc-associated target genes, suggesting an overall decrease in Myc function.  Unlike what was 
observed with Notch inhibition in T-ALL cell lines, myc transcripts were unaltered by Dll1/4 
inhibition, thus making it more likely that Notch promotes a post-translational increase in Myc 
protein levels and/or function.  Notch-inhibited 4C cells exhibited similar features as Myclo cells, 
as they expressed higher levels of Bcl2, lower levels of IFNγ and CD25, and exhibited lower 
mTORC1 activity.  Thus, it is tempting to speculate that Notch partially drives CD4+ T cell 
alloreactivity through positive regulation of Myc activity.  If this were indeed the case, this 
mechanism would be unlike the direct transcriptional regulation of myc in Notch gain-of-
function T-ALL.   
Myc functions by forming obligate heterodimers with MAX [156].  Together, they directly 
bind to DNA through their basic helix-loop-helix leucine zipper (bHLHZ) domains to regulate 
transcription.  Other bHLHZ domain-containing proteins, such as MAD, antagonize Myc 
function through recruitment of histone deacetylase complexes.  Myc protein levels are 
posttranslationally regulated through phosphorylation, ubiquitinylation, and acetylation.  
Specifically, phosphorylation of Myc at Ser-62 by Ras/MAPK, JNK, and CDK1 stabilizes Myc 
protein levels, while phosphorylation at Thr-58 by GSK3 destabilizes Myc protein levels [171, 
172]. If Notch inhibition in alloreactive T cells indeed reduces Myc protein levels, one possible 
mechanism could be through the reduction of Ras/MAPK-mediated phosphorylation of Myc.  
We will directly assess Myc protein levels within alloantigen-specific T cells during priming by 
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crossing 4C mice to GFP-c-Myc reporter mice, which express a GFP-c-Myc fusion protein from 
the endogenous Myc locus [173].  Importantly, the GFP-c-Myc fusion protein fully retains 
endogenous Myc functionality, thus serving as a useful tool for quantifying c-Myc protein levels.  
Alternatively, if Notch inhibition in alloreactive T cells reduces Myc function as opposed to Myc 
protein levels, one possible mechanism could be through the antagonism of obligate heterodimer 
formation with MAX, or through enhancement of antagonism by MAD. 
In summary, we have identified a CD4+ Tconv-intrinsic role for Notch signaling in 
alloreactivity and GVHD.  Notch-deprived CD4+ Tconv alloreactive T cells did not display overt 
defects in initial antigen sensitivity, as they exhibited preserved activation marker upregulation, 
IL-2 production, and initial proliferation.  Alloreactive T cells expressed low levels of hes1, 
while Notch inhibition did not alter pten expression, making it unlikely that Notch utilizes the 
Hes1-PTEN-AKT axis to drive alloreactivity.  Notch inhibition had no impact on myc 
transcription.  In contrast, Notch-deprived CD4+ T cells immediately acquired a defect in IFNγ 
and IL-17 production, exhibited diminished mTORC1 and Ras/MAPK activity, and failed to 
upregulate Myc-associated target genes.  Collectively, these data suggest that previously reported 
molecular mechanisms cannot account for the role of Notch in alloreactive T cells, and instead 
suggest a new set of unique mechanisms through which Notch modulates CD4+ T cell 
alloreactivity. 
  
  79 
Chapter 5 
Conclusions and Perspectives 
Despite the recent explosion in enthusiasm for CAR T cell therapy for patients with cancer, 
allogeneic bone marrow transplantation (allo-BMT) remains by far the most commonly used 
form of adoptive immunotherapy. Although allo-BMT can be highly successful, it is also linked 
to significant complications, such as GVHD, that limit its success and broad applicability. Thus, 
there is a need to better understand the pathogenesis of GVHD and to identify new pathways for 
therapeutic intervention. Notch signaling has emerged as an important regulator of T cell 
alloreactivity after allo-BMT.  In this thesis, I first explored the temporal and spatial regulation 
of Notch signaling at the onset of GVHD.  I found that nonhematopoietic Ccl19+ fibroblasts 
deliver essential Notch signals to alloreactive T cells during the first 48 hours post-
transplantation.  Next, I explored the molecular impact of Notch on alloreactive Tconv cells 
during the critical period of Notch activity.  Notch inhibition in Tconv cells did not impair early 
steps of T cell activation, preserving the initial acquisition of IL-2 and maintaining early 
proliferation.  In contrast, Notch-deprived Tconv cells failed to acquire IFNγ and IL-17 
production and displayed defects in mTORC1 and Ras/MAPK activity.  Transcriptional profiling 
revealed that Notch inhibition preserved the expression of master T helper lineage transcription 
factors, but impaired the transcription of several proinflammatory cytokines, cytokine receptors, 
and Myc-dependent target genes.  In this chapter, I will discuss the implications of my results, 
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provide predictions about the immunobiological functions of Ccl19+ fibroblasts and Notch 
signaling in T cell alloimmunity, as well as discuss future experimental directions. 
FRCs in alloimmunity and beyond 
Early studies of Notch ligand expression in DCs [124], together with the finding that DCs 
could determine Th1 or Th2 fates in CD4+ T cells through the differential expression of Delta-
like or Jagged Notch ligands [51], predicted that DCs would be responsible for the simultaneous 
presentation of alloantigen and Notch ligands to alloreactive T cells during allo-BMT.  However, 
in our studies, BM chimeras lacking Dll1 and Dll4 solely within their hematopoietic tissues 
remained sensitive to GVHD mortality (Chapter 3), thus ruling out this possibility.  Instead, our 
results revealed a critical role for Ccl19+ fibroblasts as a source of Dll1/4 Notch ligands in 
GVHD and suggest three alternative scenarios for how alloreactive T cells interact with 
alloantigens and receive Notch signals (Fig. 5.1).  In the first model, hematopoietic DCs present 
alloantigens while Ccl19+ fibroblasts deliver Notch ligands.  In the second possibility, Ccl19+ 
fibroblasts simultaneously provide both alloantigens and Notch ligands.  In the third scenario, a 
nonhematopoietic APC that is not a Ccl19+ fibroblast presents alloantigens, while Ccl19+ 
fibroblasts deliver Notch ligands. Of note, all these scenarios profoundly revise our current 
understanding of GVHD pathogenesis. 
The observation that adoptive transfer of host-derived MHC class II-expressing DCs was 
sufficient to induce disease in GVHD-resistant MHCII-/- mice provided the first suggestion that 
DCs were responsible for providing alloantigens to CD4+ T cells in vivo [174, 175].  This 
concept was consistent with the well-established role for DCs as APCs for CD4+ T cells in 
immune responses outside the context of allo-BMT.  Furthermore, BM chimera studies with  
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Figure 5.1. Three models for how alloreactive CD4+ T cells receive their alloantigens and 
Notch ligands during priming 
Hematopoietic antigen-presenting cells (APCs) are dispensable sources of Notch ligands (top panel).  
Three possible models for how alloantigen-specific T cells receive their alloantigen and Notch ligands 
(bottom panel).  In model A, hematopoietic APCs deliver alloantigens while Ccl19+ fibroblasts provide 
Notch ligands. In models B and C, hematopoietic APCs are completely dispensable for both alloantigen 
presentation and delivery of Notch ligands.  In model B, Ccl19+ fibroblasts deliver both alloantigens and 
Notch ligands.  In model C, a nonhematopoietic Ccl19- cell presents alloantigen while Ccl19+ fibroblasts 
deliver Notch ligands. 
 
MHC class I-deficient β2-microglobulin KO mice had previously demonstrated that host DCs 
were essential for delivering alloantigen during CD8+-mediated GVHD [12].  However, as the 
transferred DCs were not irradiated in the add-back studies, it was conceivable that irradiated 
host DCs would not behave in the same way.  Three recent studies suggested that this was most 
likely the case.  Antibody-mediated or genetic depletion of host conventional DCs, plasmacytoid 
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DCs, and B cells had no impact on GVHD [130, 132].  In an H-Y antigen-dependent model of 
GVHD, thymectomized BM chimeras that lacked MHC class II within their hematopoietic 
system remained sensitive to GVHD [131].  Similarly, in a parent-> F1 irradiation-dependent 
model of GVHD, BM chimeras that lacked MHC class II within donor and host hematopoietic 
tissues remained sensitive to GVHD lethality, while >60% of BM chimeras that lacked MHC 
class II within donor hematopoietic and host nonhematopoietic tissues were protected from 
GVHD lethality [130]. Collectively, these data suggested that nonhematopoietic cells could serve 
as functional APCs in the absence of functional DCs.  Thus, these recent findings would argue 
against the first model, at least for CD4+ T cell-mediated alloreactivity.  Several lines of 
evidence support the notion that FRCs and or other nonhematopoietic cells can present antigen 
through MHC class II.  Transcriptional profiling revealed that FRCs upregulate both subunits of 
MHC class II and intracellular antigen presentation components in response to inflammation 
[107].  Furthermore, FRCs by themselves can drive CD4+ T proliferation in an antigen-
dependent manner, either through direct expression of class II or through transfer of class II from 
other neighboring cells [112, 176, 177].  MHC class II expression is regulated by the master 
transcription factor class II trans-activator (CIITA), which contains four major promoters 
regions, pI, pII, pIII, pIV [178-180].  CIITA-pIV is IFNγ-dependent, and is operational in nearly 
all nonhematopoietic cell types.  For example, in an H-Y mismatched model of GVHD, liver 
endothelial cells and gut epithelial cells that were treated with IFNγ had the capacity to drive H-
Y antigen-dependent T cell proliferation in vitro [131].  Thus, both the second model, in which 
Ccl19+ fibroblasts present both alloantigen and Notch ligands, and the third scenario, in which 
Ccl19- nonhematopoietic cells present alloantigen while Ccl19+ fibroblasts present Notch 
ligands, are plausible.   
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Future studies in the lab will directly test the second model, namely the possibility that 
Ccl19+ fibroblasts present alloantigen.  To test whether Ccl19+ fibroblasts are important sources 
of alloantigens, TEa TCR transgenic CD4+ donor T cells, which recognize BALB/c-derived I-Ed 
antigen specifically in the context of I-Ab MHC class II, will be transplanted with WT TCD B6 
BM into irradiated B6 x BALB/c F1 recipients that express both the Ccl19-cre transgene and one 
copy of the floxed I-Ab allele.  In this experimental system, Ccl19+ fibroblasts would lack the 
machinery to present alloantigen to donor TEa cells, as they would lack the expression of I-Ab 
(but would retain expression of BALB/c-derived I-Ad and I-Ed), while Ccl19- cells would retain 
expression of MHC class II.  This design would circumvent the potential disruptions in immune 
homeostasis that may be present in B6 TgCcl19-cre+;H2-Ab1Δ/Δ mice, as F1 experimental mice 
could be generated by crossing B6 TgCcl19-cre+;H2-Ab1Δ/+ with BALB/c mice. Alternatively, if B6 
TgCcl19-cre+;H2-Ab1Δ/Δ do not exhibit baseline defects in immune homeostasis, they could be 
utilized as recipients of purified BALB/c CD4+ T cells and WT B6 TCD BM.  Using either 
model, if genetic inactivation of MHC class II within Ccl19+ fibroblasts results in long-term 
protection from GVHD, it would strongly suggest that Ccl19+ fibroblasts are important 
presenters of alloantigen.  If the aforementioned genetic strategies do not lead to long-term 
protection, we would have to rule out the possibility that Ccl19+ fibroblasts acquire MHC class II 
from neighboring Ccl19- cells before concluding that they are not important for alloantigen 
presentation. 
If genetic studies demonstrate that Ccl19+ fibroblasts are indeed responsible for both 
alloantigen presentation and the delivery of Notch ligands to alloreactive T cells, it is interesting 
to speculate about the location at which this would occur.  It would be entirely conceivable that 
one population of Ccl19+ fibroblast presents alloantigens, while another population provides 
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Notch ligands.  Using flow cytometry and immunofluorescence studies, I demonstrated that 
CD157+ T zone FRCs and CD21/35+ FDCs both expressed high levels of Dll4 (Chapter 3).  
Given that T cells enter the LN parenchyma through HEV “exit ramps” which are formed by T 
zone FRCs [92], it would be an obvious location within which alloantigen priming could occur.  
Preliminary studies with intravital imaging support this possibility (discussed later in 
“Molecular mechanisms of Notch in alloimmunity and beyond”).  Alternatively, alloreactive 
T cells could enter the LN parenchyma and encounter their alloantigens and Notch ligands on 
FDCs, which can present opsonized antigen, at the center of B cell follicles.  While this scenario 
would be unlikely during a normal immune response due to the strict chemokine and FRC-
dependent boundaries that restrict T cell trafficking, it is possible that normal trafficking is 
disrupted during allo-BMT and that restricted microanatomical areas become accessible to 
incoming T cells.  Supportive of this possibility, I found through static immunofluorescence 
images that 4C alloreactive T cells could localize within B cell follicles during the first two days 
post-transplantation (Chapter 3).   However, it is unclear whether alloreactive cell simply transit 
through the B follicles to reenter the T cell zone, or whether they persist inside.  Finally, in a 
third scenario, alloantigen presentation by Ccl19+ fibroblasts could occur outside of SLOs, as 
GVHD can develop in their absence [181] while we and others have observed Ccl19-Cre 
transgene activity in tissues outside of SLOs. 
We found that a single dose of Dll1/4 neutralizing antibodies at the time of transplantation 
was sufficient to confer long-term protection from GVHD.  In contrast, delaying administration 
by two days resulted in a substantial loss of clinical protection, thus identifying an early window 
of functionally important Notch signaling during allo-BMT (Chapter 3).  This narrow temporal 
window, which coincides with T cell priming, could be explained by a short duration of high 
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intensity Notch signaling, a short duration of T cell sensitivity to Notch, or both.  Two different 
scenarios could facilitate the short period of high intensity Notch signaling.  In the first scenario, 
prolonged contacts between alloreactive T cells and alloantigen-presenting cells would promote 
a substantial decline in T cell motility, allowing for the sustained delivery of Notch signals from 
a focal niche.  Upon disengagement from the immune synapse, T cells would once again increase 
their motility, resulting in decreased exposure to Notch signals.  In other words, alloantigen 
would facilitate the sustained delivery of Notch signals by Ccl19+ fibroblasts.  In the second 
scenario, alloreactive T cell would transiently traffic to a unique microenvironment that is rich in 
Notch ligands (i.e. where FDCs are present).  Upon exiting this area, alloreactive T cells would 
be exposed to lower concentrations of Notch ligands, thus dampening Notch signals.  
While our studies prominently highlight Ccl19+ fibroblasts as the key cellular sources that 
deliver Notch signals to alloreactive T cells during GVHD, it remains an open question as to 
whether our observations are generalizable to other types of T cell-driven responses.  It is 
possible that the highly inflammatory conditions that ensue after total body irradiation, in 
conjunction with the rapid disappearance of radiosensitive hematopoietic cells, are key factors 
that determine the relative importance of Ccl19+ fibroblasts in delivering Notch ligands to T 
cells.  Recent in vivo loss-of-function genetic approaches have generated conflicting results on 
this matter.  In one study, conditional deletion of Dll4 in host DCs (TgCD11c-cre; Dll4Δ/Δ) impaired 
H-Y antigen responses by adoptively transferred H-Y specific Marilyn TCR transgenic cells 
[70]. Relative to Marilyn T cells that were transferred into WT male mice, Marilyn T cells that 
were transferred into male TgCD11c-cre; Dll4Δ/Δ mice were smaller, expressed lower levels of 
activation markers, and produced less IL-2.  In a second study, transfer of OVA-specific OT-II 
TCR transgenic cells into TgCD11c-cre; Dll1Δ/Δ impaired their survival [84].  In ongoing studies that 
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were not included in this thesis, I found that Ccl19+ fibroblasts were not important cellular 
sources of Dll4 in a model of myelin oligodendrocyte glycoprotein peptide-induced experimental 
autoimmune encephalitis.  On the other hand, Notch-dependent Tfh differentiation was reported 
to proceed normally in the absence of Notch ligand expression on hematopoietic cells, and was 
exquisitely dependent on Dll4 ligands from Ccl19+ fibroblasts [123].  Furthermore, in studies 
that were not included in this thesis, I also found that Ccl19+ fibroblasts deliver Dll1/4 ligands to 
alloreactive T cells in a heterotopic model of cardiac allograft rejection. Thus, it is still unclear 
whether Ccl19+ fibroblasts provide Notch ligands during normal immune responses that occur in 
the absence of irradiation.  Further studies will be required to clarify this question, as it has 
significant implications about the mechanisms through which Notch signals are delivered to T 
cells. 
Molecular mechanisms of Notch in alloimmunity and beyond 
The recent emergence of new prophylactic strategies for GVHD, such as post-transplantation 
cyclophosphamide, has renewed enthusiasm for understanding early molecular events affecting 
alloantigen-specific T cells during their initial priming [182-185].  However, the field of 
experimental GVHD has been limited by the lack of tools for identifying alloantigen-specific T 
cells at early time points.  In parent -> F1 models of GVHD, cell proliferation and expression of 
the early activation marker CD69 were utilized to approximate the frequency of alloreactive T 
cell precursors in polyclonal donor inoculums [186].  However, in irradiation-dependent models 
of GVHD, both CD69 upregulation and cell proliferation can occur in bystander cells that are 
undergoing homeostatic proliferation independently of alloantigen (data not shown).  Thus, 
technical limitations prevented molecular analysis of alloantigen-specific T cells in irradiation-
dependent models of GVHD.  This changed with the development of TCR transgenic cells with 
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fixed antigen specificity.  However, while TCR transgenic cells were employed to assess the 
long-term impact of clinical interventions and/or specific molecular pathways on GVHD [187, 
188], there still remained a wide gap in knowledge about the molecular effects that occur during 
the early stages of priming.  We bridged this gap by establishing a new model of acute GVHD 
that utilized a clonal population of alloantigen-specific CD4+ T cells.  We envision that this 
model can be used as a broad platform to evaluate the mechanistic impact of nearly any 
therapeutic intervention, not just Notch inhibition, in alloantigen-specific T cells during priming.  
While the dynamics of pathogen-specific T cells have been characterized through intravital 
imaging, it is unclear whether alloantigen-specific T cells behave in a similar fashion.  To gain 
insights into this question, the Serody group recently performed intravital imaging studies in two 
polyclonal models of acute GVHD [189].  Allogeneic donor T cells participated in prolonged 
contacts with DCs within two hours after allo-BMT and exhibited slower instantaneous velocity 
than syngeneic donor T cells.  Furthermore, Tregs reduced the contact time between Tconv cells 
with DCs.  However, there were three major problems with this analysis that could change the 
interpretation of these results.  First, given that alloantigen-specific T cells constitute a low 
fraction of the donor inoculum, it is most likely that a majority of the observed behavior was 
attributable to bystander T cells that were not alloantigen-specific.  Second, autologous T cells 
were imaged in separately transplanted mice, suggesting that non-cell autonomous factors or 
technical variability could have contributed to differences in behavior between allogeneic and 
autologous cells.  Third, a mixture of both CD4+ and CD8+ T cells were infused into the 
recipient.  As CD8+ cells receive alloantigen from host DCs while CD4+ cells may not, their 
behavior in relation to DCs would most likely be different.  Thus, it was clear that imaging 
studies with alloantigen-specific CD4+ or CD8+ T cells needed to be performed. 
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In an effort to define the impact of Notch on early alloantigen-specific T cell dynamics in 
relation to Ccl19+ fibroblasts, I collaborated with the Huang laboratory at Case Western Reserve 
University to perform intravital multiphoton imaging studies.  In light of the caveats of the 
aforementioned Serody study, we established an alternative experimental system utilizing 
alloantigen-specific CD4+ 4C T cells.  As we knew that these cells were potent inducers of 
GVHD lethality (Chapter 4), we postulated they would serve as a good tool for intravital 
imaging analysis.  To visualize Ccl19+ fibroblasts, we generated F1 B6 x BALB/c mice that 
expressed both the Ccl19-cre transgene and the ROSA26TdTomato reporter alleles. The 
ROSA26TdTomato allele was substantially brighter than the ROSA26eYFP allele, allowing us to 
identify Ccl19+ fibroblasts with either multiphoton or confocal microscopy.  We labeled 4C 
alloantigen-specific CD4+ T cells with the cell tracker dye CMTMR, autologous F1 CD4+ T cells 
with the cell proliferation dye CFSE, transferred both populations into the same irradiated F1 
TgCcl19-cre+;ROSA26TdTomato recipients, and immediately began imaging the exposed popliteal LN 
(Fig. 5.2).   
 
 
 
 
 
 
 
 
 
Figure 5.2. Experimental design for intravital imaging of alloantigen-specific CD4+ T cells 
and Ccl19+ fibroblasts 
Alloantigen-specific 4C+ cells were labeled with CMTMR, autologous cells were labeled with CFSE, 
while recipient mice express both TgCcl19-cre and ROSA26TdTomato.  Image on the right represents a snapshot 
of the popliteal LN six hours post-transplantation. 
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Future studies will involve quantifying the instantaneous velocity and displacement ratios of 
alloantigen-specific T cells in both irradiation-dependent and irradiation-independent F1 models, 
characterizing the spatial relationship of alloantigen-specific cells to Ccl19+ fibroblasts and DCs 
during priming with a special focus on assessing whether alloantigen-specific T cells participate 
in prolonged contacts with one or both cell types, and defining the features of the 
microanatomical niches in which alloantigen-specific T cells localize.  These data will not only 
provide insights into the behavior of alloantigen-specific T cells during priming, but also provide 
clues about their interaction partners.  Of course, it will be important to characterize the effects 
of Notch inhibition on all of the aforementioned parameters.  Finally, other more exploratory 
questions could involve the use of 2C CD8+ transgenic T cells to define CD8+ alloreactivity and 
the development of strategies to image either the mesenteric LN or the spleen, two major sites to 
which alloreactive T cells immediately traffic after allo-BMT.  Altogether, these findings will 
allow the field to determine whether alloantigen-specific T cells abide by the classical three-
phase model of priming that was initially defined by von Andrian and colleagues [158, 190].  
The extraordinarily high abundance of antigen, combined with the inflammatory environment 
after allo-BMT, could conceivably result in a divergent process of T cell priming. 
One tool that would aid in future intravital imaging studies could be the development of a 
robust Notch reporter that reads out in vivo Notch signals in a specific, quantitative and dynamic 
manner.  Currently available reporters, which utilize BAC transgenes that contain tandem RBP-
Jκ binding sites upstream of a reporter gene, have failed to achieve one or more of these criteria.  
Recent work that utilized synthetic Notch receptors with swapped out intracellular transcriptional 
domains to sense extracellular stimuli could aid in this endeavor [191].  For example, mice that 
simultaneously express a tetracycline response element promoter upstream of eYFP and a 
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modified version of Notch1 that replaces the intracellular domain with a tetracycline 
transactivator could perhaps be useful. 
RNA-Seq analysis of the transcriptome of Notch-inhibited alloreactive 4C cells undergoing T 
cell priming revealed a profound impairment in the transcription of several cytokines, including 
ifng, il17a, il17f, il10, and il21. Notably, il2 and tnfa were unchanged with Notch inhibition.  
Consistent with our previous work, expression of master T helper lineage transcription factors, 
including tbx21, gata3, rorc, foxp3, were not regulated by Notch in alloreactive T cells.  Thus, it 
is unlikely that Notch exerts control over T helper lineage fate decisions.  Instead, it most likely 
functions to ensure the appropriate acquisition of effector functions.  Notably, Notch inhibition 
preserved initial proliferation of alloantigen-specific T cells, suggesting a dissociation of 
proliferation from effector function acquisition.  While my studies do not yet provide a clear 
molecular explanation for how this dissociation occurs, they provide a clear-cut reason for why 
Notch inhibition does not result in global immunosuppression. 
Our mechanistic studies with a clonal population of alloreactive T cells revealed that Notch 
inhibition also results in the delayed downregulation of CD69 after alloantigen stimulation 
(Chapter 4).  This effect was not unique to 4C cells, as we observed the same result when 
polyclonal BALB/c cells were transferred into lethally irradiated TgCcl19-cre+;Dll1Δ/Δ;Dll4Δ/Δ mice 
(data not shown).  Given that CD69 expression receives direct inputs from the TCR, these data 
suggested that Notch-deprived alloreactive T cells could be receiving a longer pulse of TCR 
signals.  As CD69 expression is also regulated by inflammatory stimuli such as Toll-like 
receptors [162] and type I IFNs [192], it is conceivable that this observation was due to a non-
cell autonomous effect.  However, assessment of Nur77-GFP levels, which has been reported to 
be insensitive to inflammatory mediators, showed similar results.  While Nur77-GFP levels 
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rapidly declined to undetectable levels in WT alloreactive cells after priming, Notch-deprived T 
cells persistently expressed Nur77-GFP.  Collectively, these findings supported the possibility 
that Notch-deprived alloreactive T cells receive a longer duration of TCR signals.  Alternatively, 
it is conceivable that Notch-deprived T cells are globally defective in protein degradation, 
resulting in delayed turnover.  This hypothesis could be tested in pulse-chase experiments with 
radioactively labeled amino acids. 
How do alloreactive T cells quantify the signals they receive during priming? How do 
alloreactive T cells determine when to disengage from their immune synapse after participating 
in prolonged contacts with APCs?  This process must be tightly controlled, as improper 
acquisition of signals can result in dysfunctional effector outcomes or ultimately, cell death.  One 
important mechanism that ensures the optimal delivery of signals is the employment of digital 
and analog elements in classical signal transduction pathways.  Analog signals can be converted 
into digital signals to form signaling thresholds.  Upon meeting the threshold for activation, T 
cells enforce negative feedback loops to turn off signaling.  For example, TCR-mediated ERK1/2 
activation results in the phosphorylation of the transmembrane scaffold LAT at Thr155 to 
diminish IP3-mediated Ca++ mobilization [193].  However, classical signal transduction pathways 
by themselves might not be sufficient for ensuring optimal signal delivery, due to their 
dependence on signal amplification.  Thus, it is conceivable that alloreactive T cells leverage the 
unique biochemistry of Notch signaling, which does not rely on signal amplification, to “count” 
signals in a more precise manner.  Alloreactive T cells could more precisely quantify the quality 
and duration of their interactions with APCs during the prolonged contact phase through the 
regulation of transcriptional targets downstream of Notch.  In the absence of Notch signals, 
alloantigen-specific T cells would lack the ability to quantify signals in a refined manner, 
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resulting in miscoordinated release from the synapse.  This model would be predicated on the 
assumption that Notch signals are delivered in parallel to alloantigen signals, which has yet to be 
demonstrated. 
Notch-deprived alloreactive T cells share some common molecular features with exhausted T 
cells, which develop during situations of persistent antigen exposure such as chronic viral 
infections and high tumor burden.  Exhausted T cells produce diminished amounts of 
proinflammatory cytokines, express higher levels of inhibitory surface markers, and persistently 
express the early activation marker, CD69 [194]. Furthermore, while exhausted CD4+ and CD8+ 
T cells exhibit divergent transcriptional programs, they share the common feature of expressing 
high levels of the T-box transcription factor, Eomes [195].  Notably, we have also observed that 
both CD4+ and CD8+ Notch-deprived alloreactive T cells express increased levels of Eomes [73].  
A subset of exhausted CD8+ T cells can be rescued with PD-1 blockade.  As both CD4+ and 
CD8+ Notch-deprived T cells exhibit higher levels of PD-1 expression at day 5 post-
transplantation, it would be interesting to test whether PD-1 inhibition in Notch-deprived T cells 
could reverse some molecular features of Notch inhibition.  One notable difference between 
Notch-deprived alloreactive T cells and exhausted T cells is their proliferative capacity, as 
polyclonal Notch-deprived alloreactive T cells demonstrate minor defects in expansion while 
exhausted T cells divide at substantially slow rates.  Understanding how Notch-deprived 
alloreactive T cells sustain cell division could provide insights into their unique behavior. 
Could Notch act as a costimulatory modulator that requires other ongoing signals to exert its 
functional effects?  This would mean that exposure of mature T cells to isolated Notch signals 
would be insufficient to alter their function.  Instead, Notch would modulate signals from other 
pathways in a context-dependent manner.  Several experimental findings support this concept.  
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First, in T cell coculture studies with antigen-pulsed artificial APCs that overexpressed different 
Notch ligands, Notch could only drive cytokine production if polarizing cytokines were included 
[67].  Second, in T cell coculture studies with antigen-pulsed artificial APCs that overexpressed 
Dll4, Notch promoted T cell activation and IL-2 production only when the B7 family member 
CD80 was also expressed on APCs [70].  Third, I observed that naïve T cells already experience 
Notch signals, as acute inhibition of Dll1/4 ligands with neutralizing antibodies or genetic 
inactivation of Dll1/4 ligands with Ccl19-cre downregulates Notch target genes in naïve T cells. 
Yet, naïve T cells from Notch-deprived DNMAML mice exhibit no obvious phenotypes on 
baseline. Thus, the consequences of Notch signaling may become apparent only when T cells 
engage in an antigen-driven immune response. However, it is important to note that in murine 
models of GVHD, Notch inhibition achieves superior clinical protection as compared to what is 
achieved with inhibition of individual costimulatory pathways.  For example, both CD28 KO and 
ICOS KO donor T cells are delayed in their induction of GVHD, but ultimately cause GVHD 
lethality [187, 196].  Thus, it is likely that Notch plays a more complicated role than simply 
acting like the classical B7 and TNF family of costimulatory molecules. 
Several interesting questions about Notch signaling in mature T cells require further 
exploration. Are the molecular effects of Notch in T cells reversible?  If not, could this explain 
the narrow window of sensitivity to Notch inhibition that we observed during allo-BMT?  
Epigenetic studies of mature T cells have revealed the highly plastic nature of CD4+ T helper 
subsets, arguing in support of reversibility [55].  Are the functional outcomes of persistent 
exposure to Notch different than that of transient exposure to Notch?  MZBs certainly require 
persistent Notch signaling for maintenance, while T-ALL cell lines require persistent Notch 
signals for their survival.  Furthermore, in vitro studies with GSI inhibitors demonstrated that 
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persistent Notch signaling is necessary for maintaining for T helper programs [69].  Do mature T 
cells experience different functional outcomes when exposed to differing levels of Notch signal 
strength?   
Therapeutic potential of Notch in T cell alloimmunity 
The finding that a single injection of Dll1/4 neutralizing antibodies conferred long-term 
protection from acute GVHD highlights the prophylactic potential of Notch inhibition for allo-
BMT patients.  Importantly, a single dose of Dll1/4 antibodies not only inhibited 
proinflammatory cytokine production by Tconv, but also expanded Tregs. As the intestine, 
thymus, and vasculature are exquisitely dependent on Dll1/4 signals for their maintenance, 
regeneration, and/or function, the efficacy of a single dose is highly encouraging.  However, it is 
unclear whether Notch inhibition would serve as an effective form of therapy for patients who 
already manifest with acute GVHD symptoms.  In fact, it is possible that Notch inhibition in 
these patients could exacerbate their intestinal problems, due to on target effects.   
While delayed Dll1/4 inhibition by two days did not achieve the same level of clinical 
protection as Notch inhibition at the time of transplantation, ~20% of the allo-BMT recipients 
were protected long-term.  In a model of cardiac allograft rejection, systemic Notch inhibition for 
the first 2 weeks after transplantation reduced the development of germinal center and plasma B 
cells, which may depend on Notch signals that extend beyond the first two days [74].  Thus, it is 
unclear whether the narrow therapeutic window for Notch inhibition is unique to acute GVHD or 
generalizable to other Notch-dependent T cell responses.  A deeper understanding of the basic 
mechanisms that regulate Notch function could shed light on this question.  Exploring the 
therapeutic potential of Dll1/4 inhibition in other alloimmune and autoimmune contexts will 
continue to serve as an exciting avenue with high translational potential. 
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The identification of fibroblastic niches that deliver Dll1/4 ligands to incoming alloreactive T 
cells opens up the possibility of targeting the niches themselves for therapeutic purposes.  One 
approach would be to target the molecular inputs that regulate Dll1/4 ligand expression within 
fibroblastic niches.  While Notch ligands are expressed within many tissues, it is plausible that 
different cell types employ distinct regulatory mechanisms to control Dll4 expression.  For 
example, it was recently reported that sex steroids selectively regulate Dll4 expression within 
thymic epithelial cells but not endothelial cells [197].  Thus, understanding how Notch ligand 
expression is enforced within Ccl19+ fibroblastic niches could lead to selective therapies that 
have few side effects. 
Within the thymus, the transcription factor Foxn1 coregulates the expression of the Notch 
ligand dll4 and T cell progenitor recruitment chemokines ccl25, cxcl12, and scf [133].  It is 
conceivable that SLOs also coregulate the expression of Notch ligands and the chemokines 
CCL19/CCL21 in an analogous fashion, allowing for FRCs to efficiently deliver both 
recruitment signals and Notch-dependent priming signals to alloreactive T cells.  While 
microarray studies of gp38+ CD31- FRCs suggest that they express low levels of foxn1, it is 
likely that only a small subset of FRCs that expresses Dll4 utilizes this regulatory network.  
Alternatively, FRCs might utilize an alternative transcription factor, such as one that defines 
mesenchymal cells, to enforce a similar transcriptional network.  Comparing the transcriptomes 
of Ccl19+ CD157+ FRCs, which are enriched for Dll4 expression, to Ccl19+ CD157- FRCs could 
provide insight into this question. 
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Chapter 6 
Materials and Methods 
 
Mice. BALB/c (H-2d), C57BL/6 (H-2b, CD45.2) [B6] and B6-CD45.1 (H-2b, CD45.1) mice were 
bred at the University of Michigan. TgMx1-cre, Dll1f/f, Dll4f/f, Foxp3-IRES-RFP, Nur77-GFP, and 
4C Rag1-/- T cell receptor transgenic mice were previously described [34, 117, 157, 162, 198].  
TgMx1-cre;Dll1f/f;Dll4f/f mice were kindly provided by Freddy Radtke.  4C Rag1-/- mice were 
kindly provided by Todd Brennan.  Nur77-GFP mice were kindly provided by Carey Lumeng.  
TgMx1-cre allows for interferon-inducible activation of Cre expression, e.g. via systemic 
administration of poly(I:C). 4C Rag1-/- mice have a monoclonal population of CD4+ T cells 
specific for the I-Ad MHC class II alloantigens, which enables tracking of alloantigen-specific T 
cells in vivo. 4C Rag1-/- mice were crossed to Nur77-GFP mice and backcrossed onto the Rag1-/- 
background. TgMx1-cre;Dll1f/f;Dll4f/f mice were maintained on the B6 background and backcrossed 
to the BALB/c background for >5 generations. Ccl19-Cre BAC transgenic mice (TgCcl19-cre) 
express Cre recombinase in FRCs under the control of a 90 kb regulatory sequence upstream of 
the Ccl19 transcriptional start site [123, 126, 139, 140].  TgCcl19-cre mice were kindly provided by 
Burkhard Ludewig and Freddy Radtke.  TgCcl19-cre mice were crossed to B6 
Dll4f/f;Dll1f/f;ROSA26eYFP mice (expressing Cre-inducible eYFP under control of the ROSA26 
promoter). 
  97 
Induction and assessment of GVHD. 6-10 week old BALB/c or 8-12 week old B6 recipients 
underwent allo-BMT as previously described [71-73]. Both females and males were used as 
recipients, and were distributed equally among experimental groups. BALB/c mice received 8.5-
9 Gy (137Cs source) 4 hours prior to allo-BMT, while B6 mice received two doses of 6 Gy (137Cs) 
separated by 3 hours. T cell-depleted bone marrow (TCD BM) was prepared with anti-Thy1.2 
antibodies and complement (Cedar Lane Laboratories) [72], resulting in >95% depletion of 
Thy1.2+ cells. BALB/c recipients received 5-10x106 TCD BM +/- 5x106 donor splenocytes, 
while B6 recipients received 10-15x106 TCD BM +/- 20x106 splenocytes. Clinical GVHD score 
and weight changes were monitored at least weekly, as described [71-73]. 
Antibody-mediated inhibition of Delta-like Notch ligands. Humanized IgG1 neutralizing 
antibodies against Dll1, Dll4 and isotype control were described previously [72, 199, 200].  
Nearly unlimited quantities of Dll1, Dll4, and isotype control antibodies were kindly provided by 
Christian Siebel and Minhong Yan at Genentech.  All antibodies were injected i.p. (5 mg/kg 
twice weekly). The potency and specificity of each antibody batch was verified by assessing 
their capacity to achieve in vivo depletion of Dll1-dependent marginal zone B cells or Dll4-
dependent thymocytes [72]. 
Generation of BM hematopoietic chimeras and GVHD induction. B6-CD45.2 TgMx1-
cre+;Dll1f/f;Dll4f/f donor mice or control littermates received 5 i.p. injections of 50 µg poly(I:C) 
(Amersham) every other day. Two weeks after the last poly(I:C) dose, 6-10 week old female B6-
CD45.1 recipients received 9 Gy of irradiation and were reconstituted with syngeneic BM from 
poly(I:C)-induced TgMx1-cre+;Dll1Δ/Δ;Dll4Δ/Δ or control littermates. Donor chimerism was 
quantified 12 weeks later by determining the relative frequency of CD45.2+ cells within mature 
cell populations in blood and spleen. Efficiency of Cre-mediated Dll1 and Dll4 recombination 
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was assessed by PCR in sort-purified blood myeloid cells using the following primers: Dll1-fwd: 
CACACCTCCTACTTACCTGA; Dll1-rev: GAGAGTACTGGATGGAGCAAG; Dll1-loxas: 
GGCGCTCAAAGGATATGGGA; Dll4-fwd: GTGCTGGGACTGTAGCCACT; Dll4-rev: 
TGTTAGGGATGTCGCTCTCC; Dll4-revdel: CTCGTCTGTTCGCCAAATCTTAC. 
BM chimeras were rested at least 12 weeks to allow for establishment of steady-state 
hematopoiesis before GVHD induction. BM chimeras were irradiated with two doses of 5.5 Gy 
each (137Cs) separated by 3 hours, and received 8x106 TCD BM +/- 30x106 splenocytes from 
BALB/c donors (or syngeneic B6 donors as negative control). Clinical GVHD score and weight 
changes were monitored at least weekly [71-73]. 
Lymph node stromal cell isolation. Stromal cells were isolated from LNs using a modified 
version of a previously described protocol [106, 123]. Briefly, peripheral LNs (cervical, axial, 
brachial, inguinal) from unirradiated or irradiated mice were coarsely chopped with a scalpel and 
incubated at 37°C for 15 minutes in digestion solution containing DMEM, 2% FBS, 1.2 mM 
CaCl2, penicillin/streptomycin, 1.0 mg/mL collagenase IV (Invitrogen) and 40 µg/mL DNAse I 
(Roche). Samples were pipetted gently and reincubated at 37°C until all solid material appeared 
to be dissolved. Suspensions were filtered through a 70 µM strainer and analyzed by flow 
cytometry. 
Flow cytometry. The following antibodies were from BioLegend: anti-CD4, CD8α, CD19, 
CD11c, CD11b, F4/80, PDCA1, B220, MHCII, CD44, CD62L, podoplanin/gp38, CD31, Ter119, 
CD157, CD44, CD25, CD21/35, CD45, TCRβ, H-2Kb, H-2Kd, IFNγ, TNFα and IL-2. Anti-
FoxP3 antibodies were from eBioscience. For assessment of T cell cytokine production, donor 
splenocytes were stimulated with plate-bound anti-CD3 (2.5 µg/mL, clone 145-2C11) and anti-
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CD28 (2.5 µg/mL, clone 37.51) for 2-3 hours prior to addition of monensin (Golgistop, BD 
Biosciences). Samples were fixed and stained for intracellular proteins per manufacturer’s 
instructions. Flow cytometric analysis was performed on a 3-laser Fortessa or 4-laser FACS 
AriaII/III (Becton Dickinson). Dead cells were excluded with DAPI (Sigma Aldrich) or Zombie 
Aqua fixable viability dye (Biolegend). 
Immunofluorescence microscopy. LN and spleens were fixed in 1% PFA for 2 hours, sunk in 
30% sucrose overnight, and embedded/frozen in Tissue-Tek OCT in an ethanol/dry ice bath. 
Staining of 6-8 µm thin cryosections was performed for 60’ or overnight at room temperature 
using the following antibodies: monoclonal anti-CD3ε (145-2C11), B220 (RA3-6B2), CD35 
(8C12), podoplanin/gp38 (8.1.1), MAdCAM-1 (Meca-89) and polyclonal goat anti-Dll4 
(AF1389; R&D systems). Secondary antibodies were: donkey anti–rat biotin, donkey anti–rat 
Cy3, donkey anti–rabbit Cy3, donkey anti–sheep APC (Jackson ImmunoResearch), streptavidin 
Alexa Fluor 488, donkey anti–rabbit Alexa Fluor 647 (both Invitrogen). For Dll4 labeling, 
primary antibodies were detected using a biotinylated donkey anti–goat IgG followed by HRP-
coupled streptavidin (Jackson ImmunoResearch) and tyramide Signal Amplification (Invitrogen) 
according to the manufacturer’s instructions, but using a borate buffer (0.1 M in PBS, pH 8.5) for 
tyramide dilution. eYFP was detected using a rabbit anti-GFP antibody followed by Alexa Fluor 
488–conjugated donkey anti–rabbit IgG (both Invitrogen). Images were acquired on an 
AxioImager.Z1 microscope with an AxioCam, and were processed in Adobe Photoshop. 
Specifically, image contrast was adjusted using the Levels tool, while image sharpness was 
improved with the Unsharpen Mask command. Tissue sections were stained with three different 
fluorochromes, but processed images were often simplified into two color images with ImageJ’s 
“split channels” and “merge channels” functions. 
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EdU incorporation and detection. Mice were injected i.p with 2.5 mg/mL EdU 12 hours prior 
to tissue collection. LN and spleen were fixed in 1% PFA for 2 hours, sunk in 30% sucrose 
overnight, and embedded and frozen in OCT in an ethanol/dry ice bath. EdU was detected with 
Click-iT EdU Alexa Fluor 488 imaging kit (Molecular Probes), per manufacturer’s instructions. 
Quantitative real-time PCR. Donor T cells or host stromal cells were sort-purified directly into 
TRIzol (Invitrogen). Total RNA was extracted with phenol/chloroform and purified with RNeasy 
Micro kit (Qiagen). cDNA was generated with SuperScript II (Invitrogen), and subjected to 
quantitative PCR with either Taqman or SYBR Green PCR Master Mixes on Mastercycler ep 
realplex (Applied Biosystems). Gene expression analysis was performed using the following 
primers: dtx1 (Mm00492297_m1, Applied Biosystems); hes1 (Mm01342805_m1, Applied 
Systems); Hprt-fwd: CTCCTCAGACCGCTTTTTGC, Hprt-rev: 
TAACCTGGTTCATCATCGCTAATC; Il7-fwd: GTGCCACATTAAAGACAAAGAAG; Il7-
rev: GTTCATTATTCGGGCAATTACTATC. Relative gene expression was determined via the 
ΔΔCT method, with normalization to hprt. 
Isolation of 4C alloreactive T cells. 4C cells were isolated from spleen and LN using an 
enzymatic digestion protocol.  Spleen and LNs were finely chopped with a scalpel and incubated 
at 37°C for 20 minutes in 2 mL digestion solution containing RPMI, 0.75 mg/mL collagenase IV 
(Invitrogen), 0.2 mg/mL collagenase D (Roche), and 40 µg/mL DNAse I (Roche). Samples were 
then vigorously aspirated and expirated with a 1 mL pipette to disrupt the organ capsule, and 
undissolved organ fragments was allowed to settle for 2 min.  Dissolved material was then 
transferred into 10 mL of FACS buffer (PBS + 4% FBS + 2 mM EDTA), while undissolved 
fragments were resuspended in 2 mL of new digestion solution.  Samples were pipetted 
continuously for 10 min, after which undissolved organ fragments were allowed to settle for 2 
  101 
min.  Dissolved material was added to the same 10 mL of FACS buffer, while undissolved 
fragments were once again resuspended in 2 mL digestion solution.  Cells were pipetted 
vigorously for another 10 min, until all solid material appeared to be dissolved.  Suspensions 
were filtered through a 70 µM strainer and utilized for downstream applications. 
Phosphoflow. Samples were stained with surface markers for 15 min on ice, washed twice with 
FACS buffer, and fixed in 4% PFA for 30 min on ice.  Samples were pelleted and permeabilized 
with ice-cold 90% methanol for 30 min on ice.  Samples were then washed twice in FACS 
buffer, and samples were stained overnight with 100 uL intracellular antibody cocktail mix.  
Samples were acquired the next day. 
RNA-Seq analysis. 10,000 4C cells were sort-purified directly into TRIzol.  Total RNA was 
extracted with phenol/chloroform and purified with RNAEasy PLUS Micro kit (Qiagen) to 
remove contaminating DNA.  Total RNA was depleted of ribosomal RNA with Ribogone 
columns (Clontech).  RNA-Seq libraries were prepared with the SMARTer Ultra-Low input 
stranded kit and sequenced using the Illumina Hi-Seq platform.  For bioinformatics analysis, 
Clontech SMARTer adapters were trimmed, and raw reads were aligned to the UCSC mm10 
reference genome using TopHat and Bowtie.  Cufflinks/CuffDiff were utilized for differential 
expression analysis. 
Statistical analysis. Sample size for in vivo mouse experiments was determined empirically 
based on prior experience, and used to calculate power with the ‘pwr’ statistical package in R. 
After assessing for normality of data with the Shapiro-Wilk test, variances of different treatment 
groups were compared with a two-tailed F-test. Means of two different treatment groups were 
compared with a two-tailed unpaired Student’s t test only if they had statistically similar 
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variances. Significance was calculated and noted as *, p < 0.05; **, p < 0.01; *** p < 0.001. 
Survival curves were compared using Log-rank (Mantel-Cox) test. Bar graphs were generated 
with GraphPad Prism. 
Ethics statement. All experiments were performed according to NIH guidelines and approved 
by the University of Michigan’s Committee on Use and Care of Animals.  
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